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Abstract 
Introduction 
   Improvement of physicochemical properties of tablets and make quality control 
for them is the duty of pharmaceutical efforts, and the effervescent tablets are 
palatable dosage form for patient due to easy swallow and ability to mask the bitter 
taste for many drugs.  
Objectives 
Thus the study aimed to formulate ciprofloxacin hydrochloride as effervescent tablet 
and compare it with five locally marketed ciprofloxacin hydrochloride coated tablets 
(three local brands and two imported brands). 
Methodology 
   The study was carried out at the department of pharmaceutics - faculty of 
pharmacy-University of Khartoum, department of pharmaceutics- faculty of 
pharmacy- Omdurman Islamic University, department of pharmaceutics-faculty of 
pharmacy-The National Ribat University and department of microbiology-
Omdurman Ahlia University. The samples were selected from different batch 
numbers randomly and the physicochemical experiments were carried out according 
to monographs and microbiological sensitivity test was also done.  The second part 
of the research is a formulation of the drug as an effervescent tablet by two methods 
(direct compression and wet granulation). The bitter taste was masked by saccharine 
as sweeting agent furthermore the effervescent effect of citric acid, tartaric acid and 
sodium bicarbonate lead to improve the taste of the drug. Also the Guar used as 
binding agent lead to hide the taste. The vanillin which was used as flavoring agent 
also enhances the palatability.  
Results and Discussion  
      The formulated tablets passed all the fundamental testes in the monograph, and 
also microbiological sensitivity test was done against (Escherichia coli, Salmonella 
typhi, Salmonellapara typhi and Staphylococcus aureus ) and then the results were 
compared to select the suitable one. A compression was done between two formulae 
of wet granulation method (the increase of binder concentration and die size 
change).   This study showed that formulating the drug as effervescent tablet by wet 
granulation method (low binder) concentration and die cavity thirteen or twenty is 
the suitable one and that might lead to increase the drug effectiveness, therapeutic 
effect and decrease the ciprofloxacin resistance as well as increase patient 
acceptability due to formulating the drug as effervescent tablet consideration to take 
into previous studies.   
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      1. Introduction and literature review 
 
1.1. Introduction: 
   Drug substances most frequently administered orally by means 
of solid dosage forms such as tablets and capsules. (1)   
1.1.1. Tablets Definition: 
  Tablets may be defined as solid pharmaceutical dosage forms 
containing drug substance with or without suitable diluents and 
prepared by either compression or molding methods. (1)  
1.1.2. The Oral Route: 
   The oral route is the most common way of administering drugs, 
and among the oral dosage forms tablets of various different types 
are the most common. (1) 
1.1.3. Excipients: 
    Tablets contain a number of inert materials in addition to active 
ingredient known as additives or excipients. These include 
diluents, binders, glidants and lubricants. (1) 
1.1.4. Tablet Properties: 
1.1.4.1. Characteristics of Ideal Tablet: 
    Free of defect, such as: (chips, cracks and discoloration), has  
the strength to withstand the mechanical stresses of production, 
physically and chemically stable over time and release the 
medicinal agents in predictable and reproducible manner. (1) 
1.1.4.2. Advantages: 
 A Simplicity and economy of preparation. 
Stability and convenience in packaging, shipping and dispensing. 
Accuracy of dosage. 
Compactness. 
Blandness of taste. 
Ease of administration. 
Less shelf space needed. 
Simple to identify. 
Best suited to large scale production. (1) 
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1.1.4.3. Disadvantages: 
    Some drugs resist compression into tablets: (e.g. those with poor 
wetting slow dissolution properties, intermediate to large doses, 
optimum absorption high in gastro intestine tract, or any one of 
these feature) may be difficult to formulate to provide adequate bio 
availability. 
   Some drugs (bitter tasting drugs, with an objectionable odor, and 
those sensitive to oxygen or atmospheric moisture) need to be 
coated. (1) 
1.1.4.5. Shapes: 
    Tablets differ greatly in (shape, size and weight) depending on 
the amount of drug substance present and intended method of 
administration : ( Oval, Oblong, Cylindrical and Triangular). (1) 
1.1.5. Types of Tablets: 
1.1.5.1. Compressed Tablets: 
    These tablets are formed by compression and contain no special 
coating made from powdered, crystalline, or granular materials 
alone or in combination with binder’s disintegrants, colourent, 
lubricant, or control release polymer.(1)  
1.1.5.2. Sugar Coated Tablets: 
   These are compressed tablets containing a sugar coating such 
coating may be colored and are beneficial in covering up drug 
substances possessing objectionable tastes or masking and 
protecting material sensitive to oxidation. (1) 
1.1.5.3. Film Coated Tablets: 
   These are compressed tablet that are covered with a thin layer or 
film of water- soluble material. A number of polymeric substances 
with film – forming properties may be used. Film coating imparts 
the same general characteristics as sugar coating, with the added 
advantage of a greatly reduced time period required for the coating 
operation. (1) 
1.1.5.4. Enteric Coated Tablets: 
   These are compressed tablets coated with substances that resist 
solution in gastric fluid but disintegrate in the intestine. Enteric 
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coatings can be use for tablets containing drug substances that are 
inactivated or destroyed in the stomach, for those that irritate the 
mucosa, or as a means of delayed release of the medication. (1) 
1.1.5.5. Controlled Release Tablets: 
   Compressed tablets can be formulated to release the drug slowly 
over a prolonged period of time. Hence, these dosage forms have 
been referred to as prolonged- release or sustained-release dosage 
forms as well. These tablets (as well as capsule versions) can be 
categorized into three types: 
· Those that respond to some physiological condition to release 
the drug, such as enteric coatings. 
· Those that release the drug in a relatively steady, controlled 
manner. 
· Those that combine combinations of mechanisms to release 
pulse of drug, such as repeat – action tablets. (1)  
1.1.5.6. Tablets for Solution: 
  Compressed tablets to be used for preparing solutions or 
imparting given characteristics to solutions must be labeled to 
indicate that they are not to be swallowed. Examples of these 
tablets are Halzone Tablets for solution and Potassium 
Permanganate Tablets for solution. (1) 
1.1.5.7. Effervescent Tablets: 
  Tablet formulations may be rendered effervescent for several 
reasons, including improvement of their disintegration 
characteristics and their taste. The first effervescent tablets were 
essentially derived from the mildly purgative effervescent mixture 
known as a Seidlitz powder, but today the most popular have 
acetyl salicylic acid as their main ingredient. Effervescence is 
derived by the reaction which takes place between alkali metal 
carbonates, or bicarbonates, and citric and/or tartaric acids, to 
release carbon dioxide. Most formulations call for an acid 
concentration in excess of the stoichiometric requirement, as this 
improves palatability because of its ability to solubilize the drug. It 
is also favored in sucrose – containing mixtures because it has less 
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caramelizing tendency. Where the active ingredient is soluble, 
other ingredients should, if possible, be selected to yield a clear 
solution by use of an appropriate soluble lubricant, preferably a 
nonionic surfactant which can also solubilize any volatile oil 
flavoring present. (1) 
1.1.5.8. Compressed Suppositories: 
  Vaginal suppositories such as Metronidazole tablets are prepared 
by compression. Tablets for this use usually contain lactose as the 
diluents. (1) 
1.1.5.9. Buccal and Sublingual Tablets: 
   These are small, flat, oval tablets. Tablets intended for buccal 
administration by inserting into the buccal pouch may dissolve or 
erode slowly; therefore, they are formulated and compressed with 
sufficient pressure to give a hard tablet. Progesterone tablets may 
be administered in this way. 
   Some newer approaches use tablets that melt at body 
temperatures. The matrix of the tablet is solidified while the drug is 
in solution. After melting, the drug is automatically in solution and 
available for absorption, thus eliminating dissolution as a rate – 
limiting step in the absorption of poorly soluble compounds.  
Sublingual tablets, such as those containing Nitroglycerin, 
isoproterenol hydrochloride, or erythrityl tetranitrate, are placed 
under the tongue. Sublingual tablets dissolve rapidly, and the drug 
substances are absorbed readily by this form of administration. (1) 
1.1.5.10. Chewable Tablets: 
   Tablets which are to be broken and chewed in between the teeth 
before ingestion. they are given to the children who have difficulty 
in swallowing, or the adults who dislike swallowing. These tablets 
should have very acceptable taste and flavor, and produce cool 
sweet taste. Examples are Antacid tablet and multi vitamins. (1) 
1.1.5.11. Lozengens Tablets: 
   These tablets should not disintegrate in oral cavity but should 
dissolve slowly in the mouth to produce continuous effect on the 
mucous membrane of the throat. They can be produced by molding 
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as well as compression method. The formulation must contain 
sweeting agent and flavoring agent. (1) 
1.1.5.12. Implants Tablets: 
  Are small tablets for insertion under the skin by giving a small 
surgical cut into the skin. Implants are prepared to provide a slow 
and continuous release of the drug over prolonged periods they 
must be under aseptic condition and packed in unit dose sterile 
containers. (1) 
1.1.5.13. Layered Tablets: 
   These are the compressed tablet in which the granules of 
incompatible substances are compressed into two or more layers 
successively in the same tablet. (1) 
1.1.5.14. Molded Tablets: 
   Usually are made from moist material using triturate mold that 
gives them the shape of cut section of cylinder – such tabs are 
completely and rapidly soluble.  The problem of these tablets is the 
failure to find a lubricant that completely water soluble, such as 
dispensing tablets (1): 
1.1.6. Tablet Excipients: 
  Tablets are manufactured by wet granulation/dry granulation or 
direct compression.Regardless of manufacture, tablet for oral 
ingestion usually contain excipients, components added to the 
active ingredient that have special function. (1) 
1.1.6.1. Diluents: 
  Fillers are designed to make up the required bulk of the tablet 
when the drug small amount is in adequate. (1) 
1.1.6.1.1. Function of Diluents: 
 Improve the cohesion. 
 Permit use of direct compression or promote flow. 
1.1.6.1.2. Selection of Diluents: 
 Based partly on: 
 Experience of the manufacturer. 
 Diluents cost. 
 Compatibility with the other tablet ingredients. (1) 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϲ 
 
1.1.6.1.3. Common Diluents: 
 Kaolin – lactose – mannitol – starch. (2)  
1.1.6.2. Binders and Adhesive: 
 Materials added in either dry or liquid form to: 
Promote the granulation process. 
  Promote cohesiveness of compacts during the compression. If the 
drug substance is affected by an aqueous binder, a non aqueous 
binder can be used, or the binder can be added dry. The binding 
action is more effective when it is mixed in liquid form. 
The amount of binder or adhesive used depends on the 
manufacturer experience and the other tablet ingredients. Over 
wetting usually results in hard granules. (2) 
1.1.6.3. Disintegrantes: 
   A disintegrante is a substances or a mixer of substances added to 
a tablet to facilitate its breakup or disintegration after 
administration. The active ingredient must be released from the 
tablet matrix as efficiently as possible to allow rapid dissolution. 
Materials serving as the disintegrants have been classified 
chemically as starches, clays, celluloses, algins, gums and cross – 
linked polymers. (2)       
1.1.6.4. Lubricants: 
   Lubricants have a number of functions in tablet manufacture. 
They prevent adhesion of the tablet material to the surface of the 
dies and punches, reduce interparticle friction, facilitate the 
ejection of the tablets from the die cavity, and may improve the 
rate of flow of the tablet granulation.Commonly used lubricants 
include talc, magnesium stearate, calcium stearate, stearic acid, 
hydrogenated vegetable oils, and polyethylene glycol. Most 
lubricants, with exception of talc are used in concentrations below 
1%. When used alone, talc may require concentrations as high as 
5%. Lubricants are in most cases hydrophopic materials. Poor 
selection or excessive amounts can result in water proofing the 
tablets, resulting in poor tablet disintegration and/or delay the 
dissolution of the drug substances. Thus the addition of the proper 
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lubricant is highly desirable if the material to be tableted tends to 
stick to the punch and dies. (2)           
1.1.6.5. Anti Adherents: 
   Reduce sticking or adhesion of the tablet granulation or powder 
to faces of the machine or to the die wall. (1) 
1.1.7. Bioavailability – Physicochemical and Dosage Form 
Factors: 
   The discussion of the physicochemical properties of the drug and 
dosage form factors that influence bioavailability. First if the drug 
to be absorbed needs to be in solution, and secondly to pass across 
the membrane  . The physicochemical properties of the drug that 
will influence its passage into solution and transfer across 
membranes include its dissolution rate, pKa, lipid solubility, 
chemical stability and Complexation potential. (3) 
1.1.8. Physicochemical Factors Influencing Bioavailability: 
1.1.8.1. Dissolution and Solubility: 
   Solid drugs need to dissolve before they can be absorbed. The 
dissolution of drugs can be described by the Noyes – Whitney 
equation. This equation, first proposed in 1897, describes the rate 
of dissolution of spherical particles when the dissolution process is 
diffusion controlled and involves no chemical reaction (3): 
 
 
 Where  is the rate of dissolution of the drug particles,  is 
the diffusion coefficient of the drug in solution in the 
gastrointestinal fluids,  is the effective surface area of the drug 
particles in contact with the gastrointestinal fluids,  is the 
thickness of the diffusion layer around each drug particle,  is the 
saturation solubility of the drug in solution in the diffusion layer 
and  is the concentration of the drug in the gastrointestinal 
fluids.(3)  
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1.1.8.1.1. Physiological Factors Affecting the Dissolution Rate 
of Drugs: 
  The environment of the gastrointestinal tract can affect the 
parameters of the Noyes – Whitney equation (1) and hence the 
dissolution rate of a drug. For instance, the diffusion coefficient,  
of the drug in the gastrointestinal fluids may be decreased by the 
presence of substances that increase the viscosity of the fluids. 
Hence the presence of food in the gastrointestinal tract may cause a 
decrease in dissolution rate of a drug by reducing the rate of 
diffusion of the drug molecules away from the diffusion layer 
surrounding each undissolved drug particle. Surfactants in gastric 
juice and bile salts will affect both the wetability of the drug, and 
hence the effective surface area ( ), exposed to gastrointestinal 
fluids, and the solubility of the drug in the gastrointestinal fluids 
via micellization. The thickness of the diffusion layer ( ) will be 
influenced by the degree of agitation experienced by each drug 
particle in the gastrointestinal tract. (3) 
 
Figure (1-1)    
  Hence an increase in gastric and/or intestinal motility may 
increase the dissolution rate of a sparingly soluble drug by 
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decreasing the thickness of the diffusion layer around each drug 
particle. The concentration, , of drug in solution in the bulk of the 
gastrointestinal fluids will be influenced by such factors as the rate 
of removal of dissolved drug by absorption through the 
gastrointestinal – blood barrier, and by the volume of fluid 
available for dissolution, which will be dependent on the position 
of the drug in the gastrointestinal tract and the timing with respect 
to meal intake. In the stomach, the volume of fluid in the diet. 
According to the Noyes – Whitney equation a low value of  will 
favor more rapid dissolution of the drug by virtue of increasing the 
value of the term . In the case of drugs whose absorption is 
dissolution – rate limited, the value of  is normally kept very low 
by absorption of the drug. Hence dissolution occurs under sink 
conditions, that is, under conditions such that the value of  
approximates to . Thus for the dissolution of a drug from the 
gastrointestinal tract under sink conditions the Noyes – Whitney 
equation can be expressed as (3): 
 
1.1.9. Drug Factors Affecting Dissolution Rate: 
   Drug factors that can influence the dissolution rate are the 
particle size, the wetability, the solubility and the form of the drug 
(whether salt or a free form, crystalline or amorphous). (3) 
1.1.9.1. Surface Area and Particle Size Reduction: 
   According to Eqn (1) an increase in the total surface area of drug 
in contact with the gastrointestinal fluids will cause an increase in 
dissolution rate. Provided that each particle of drug intimately 
wetted by the gastrointestinal fluids, the effective surface area 
exhibited by the drug. Hence the smaller the particle size greater 
the effective surface area exhibited by a given mass of drug, and 
the higher the dissolution rate. Particle size reduction is thus likely 
to result in increased bioavailability, provided the absorption of the 
drug is dissolution – rate limited. One of the classic examples of 
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particle size effects on the bioavailability of poorly soluble 
compounds is that of griseofulvin, where a reduction of particle 
size from about 10 m to 2.7 m was shown to produce 
approximately double the amount of drug absorbed in humans. 
Many poorly soluble, slowly dissolving drugs are routinely 
presented in micronized form to increase their surface area. (3) 
1.1.9.2. Solubility in the Diffusion layer : 
   The dissolution rate of a drug under sink conditions, according to 
the Noyes – Whitney equation, is directly proportional to its 
intrinsic solubility in the diffusion layer surrounding each 
dissolving drug particle, . The aqueous solubility of a drug is 
dependent on the interactions between molecules within the crystal 
lattice, intermolecular interactions with the solution in which it is 
disolved, and the entropy changes associated with fusion and 
dissolution. In the case of drugs that are weak electrolytes, their 
aqueous solubility is dependent on pH. Hence in the case of an 
orally administered solid dosage form containing a weak 
electrolyte drug, the dissolution rate of the drug will be influenced 
by its solubility and the pH in the diffusion layer surrounding each 
dissolving drug particle. (3) 
1.1.9.3. Salts: 
    The dissolution rate of a weakly acidic drug in gastric fluid    
(pH 1 – 3.5) will be relatively low. If the pH in the diffusion layer 
could be increased, then the solubility, , exhibited by the acidic 
drug in this layer, and hence its dissolution rate in gastric fluids, 
would be increased even through the bulk pH of gastric fluids 
remained at the same low value. The pH of the diffusion layer 
would be increased if the chemical nature of the weakly acidic 
drug were changed from that of the free acid to a basic salt, for 
example the sodium or potassium form of the free acid. The pH of 
the diffusion layer surrounding each particle of the salt form would 
be higher than the low bulk pH of the gastric fluids because of the 
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neutralizing action of the strong ions (Na+ or K+) ions present in 
the diffusion layer. (3) 
1.1.9.4. Crystal Form: 
   Many drugs can exist in more than one crystalline form, e.g. 
chloramphenicol palmitate, cortisone acetate, tetracyclines and 
sulphathiazole. This properly is referred to as polymorphism and 
each crystalline form is known as a polymorph.A classic example 
of the influence of polymorphism on drug bioavailability is 
provided by chloramphenicol palmitate. This drug exist in three 
crystalline forms designated A, B and C. At normal temperature 
and pressure A is the stable polymorph, B is the metastable 
polymorph and C is the unstable polymorph.In addition to different 
polymorphic crystalline forms, a drug may exist in an amorphous 
form. Because the amorphous form usually dissolves more rapidly 
than the corresponding crystalline form(s), the possibility exists 
that there will be significant differences in the bioavailability 
exhibited by the amorphous and crystalline forms of drugs that 
show dissolution – rate limited bioavailability.A classic example of 
the influence of amorphous versus crystalline forms of a drug on 
its gastrointestinal bioavailability is provided by that of the 
antibiotic novobiocin. The more soluble and rapidly dissolving 
amorphous form of novobiocin was readily absorbed following 
oral administration of an aqueous suspension to humans and dogs. 
However, the less soluble and slower –dissolving crystalline form 
of novobiocin was not absorbed to any significant extent. The 
crystalline form was thus therapeutically ineffective. (3) 
1.1.9.5. Solvent: 
   Another variation in the crystalline form of a drug can occur if 
the drug is able to associate with solvent molecules to produce 
crystalline forms known as solvents. When water is the solvent, the 
solvent formed is called a hydrate. Generally the greater the 
solvation of the crystal, the lower is the solubility and dissolution 
rate in a solvent identical to the solvation molecules. As the 
solvated and non-solvated forms usually exhibit differences in 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϭϮ 
 
dissolution rates, they may also exhibit differences in 
bioavailability, particularly in the case of poorly soluble drugs that 
exhibit dissolution-rate limited bioavailability e.g. Ampicillin. A 
valuable example is that of the antibiotic Ampicillin: the faster-
dissolving anhydrous form both hard gelatin capsules and an 
aqueous suspension than was the lower-dissolving trihydrate form. 
Bioavailability is reflected by a significantly rate and extent of 
absorption and over doubling of the bioavailability of the 
anhydrous form. (3) 
1.1.10. Factors Affecting the Concentration of Drug in Solution 
in the Gastrointestinal Fluids: 
   The rate and extent of absorption of a drug depends on the 
effective concentration of that drug, i.e. the concentration of drug 
in solution in the gastrointestinal fluids which is in an absorbable 
form. Complexation, micelles solubilization, absorption and 
chemical stability are the principle physicochemical properties that 
can influence the effective drug concentration in the 
gastrointestinal fluids. (3) 
1.1.10.1. Complexation: 
   Complexation of a drug may occur within the dosage form 
and/or in the gastrointestinal fluids, and can be beneficial or 
detrimental to absorption. 
Complexation is sometimes used to increase drug solubility, 
particularly of poorly water – soluble drugs. One class of 
complexion agents that is increasingly being employed is the 
cyclodextrin family. (3) 
1.1.10.2. Micellar Solubilizaion: 
   Micellar solubiization can also increase the solubility of drugs in 
the gastrointestinal tract. The ability of bile salts to solubilise drugs 
depends mainly on the lipophilicity of the drug. (3) 
1.1.10.3. Adsorption: 
   The concurrent administration of drugs and medicines containing 
solid adsorbents (e.g. anti diarrheal mixtures) may result in the 
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adsorbents interfering with the absorption of drugs from the 
gastrointestinal tract. 
And this is good example for effect of pharmaceutical dosage form 
on the bioavailability. (3) 
1.1.11. Chemical Stability of the Drug in the Gastrointestinal 
Fluids: 
    If there is instability in the gastrointestinal fluids the amount of 
drug that is available for absorption will be reduced and its 
bioavailability reduced. Instability in gastrointestinal fluids is 
usually caused by acidic or enzymatic hydrolysis. When a drug is 
unstable in gastric fluid its extent of degradation would be 
minimized (and hence its bioavailability improved) if it exhibited 
minimal dissolution in gastric fluid but still rapid dissolution in 
intestinal fluid. The concept of delaying the dissolution of a drug 
until it reaches the small intestine has been employed to improve 
the bioavailability of erythromycin in the gastrointestinal tract. 
Enteric coating resists gastric fluid but disrupts or dissolves at the 
less acid pH range of the small intestine. An alternative method of 
protecting a susceptible drug as in the case of erythromycin is the 
administration of chemical derivatives of the parent drug. These 
derivatives, or prodrugs, exhibit limited solubility (and hence 
minimal dissolution) in gastric fluid but, once in the small 
intestine, liberate the parent drug to be absorbed. For instance, 
erythromycin stearate, after passing through the stomach un 
dissolved, dissolves and dissociates in the intestinal fluid, yielding 
the free base erythromycin that is absorbed. Instability in 
gastrointestinal fluids is one of the reasons why many peptides – 
like drugs are poorly absorbed when delivered via the oral route. 
And also poorly water – soluble drugs are increasingly becoming a 
problem in terms of obtaining the satisfactory dissolution within 
the gastrointestinal tract that is necessary for good bioavailability. 
It is not only existing drugs that cause problems, but it is the 
challenge of medicinal chemists to ensure that new drugs are not 
only active pharmacologically but have enough solubility to ensure 
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fast – enough dissolution at the site of administration, often the 
gastrointestinal tract. This is a particular problem for certain 
classes of drugs, such as the HIV protease inhibitors, the 
glycoprotein IIb/IIIa inhibitors, and many anti – infective and 
anticancer drugs.  Medicinal chemists are using approaches such as 
introducing ionizable groups, reducing melting points, changing 
polymorphs or introducing pro drugs to improve solubility. 
Pharmaceutical scientists are also applying a wide range of 
formulation approaches to improve the dissolution rate of poorly 
soluble drugs. These include formulating in the nano – size range; 
formulating in a solid solution or dispersion or self – emulsifying 
drug delivery system; stabilizing the drug in the amorphous form 
or formulating with cyclodextrins. Many drug delivery companies 
thrive on technologies designed to improve the delivery of poorly 
soluble drugs. (3) 
1.1.11.1. Drug Absorption: 
   Once the drug has successfully passed into solution it is available 
for absorption. Many physiological factors were shown to 
influence drug absorption. Absorption, and hence the 
bioavailability of a drug once in solution, is also influenced by 
many drug factors, in particular its pKa, lipid solubility, molecular 
weight, the number of hydrogen bonds in the molecule and its 
chemical stability. 
There are many properties of the drug itself that will influence its 
passage into solution in the gastrointestinal tract and across the 
gastrointestinal membrane, and hence its overall rate and extent of 
absorption. (4) 
1.1.12. Dosage Form Factors Influencing Bioavailability: 
   The rate and/or extent of absorption of a drug from the 
gastrointestinal tract have been shown to be influenced by many 
physiological factors and by many physicochemical properties 
associated with the drug itself. The bioavailability of a drug can 
also be influenced by factors associated with the formulation and 
production of the dosage form. Increasingly many dosage forms 
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are being designed to affect the release and absorption of drugs, for 
example controlled – release systems and delivery systems for 
poorly soluble drugs. (3) 
1.1.12.1. Influence of the Type of Dosage Form: 
   The type of dosage form and its method of preparation or 
manufacture can influence bioavailability. Thus, whether a 
particular drug is incorporated and administered in the form of a 
solution, a suspension or solid dosage form can influence its rate 
and/or extent of absorption from the gastrointestinal tract. The type 
of oral dosage form will influence the number of possible 
intervening steps between administration and the appearance of 
dissolved drug in the gastrointestinal fluids, i.e. the type of dosage 
form will influence the release of drug into solution in the 
gastrointestinal fluids. 
   In general, drugs must be in solution in the gastrointestinal fluids 
before absorption can occur. Thus the greater the number of 
intervening steps, the greater will be the number of potential 
obstacles to absorption and the greater will be the likelihood of that 
type of dosage form reducing the bioavailability exhibited by the 
drug. Hence the bioavailability of a given drug tends to decrease in 
the following order of types of dosage form: aqueous solution > 
aqueous suspensions > solid dosage forms (e.g. hard gelatin 
capsules or tablets). Although this ranking is not universal, it does 
provide a useful guideline. In general, solutions and suspensions 
are the most suitable for administering drugs intended to be rapidly 
absorbed. However, it should be noted that other factors (e.g. 
stability, patient acceptability etc.) can also influence the type of 
dosage form in which a drug is administered via the 
gastrointestinal route. (3) 
1.1.12.2. Influence of Excipients for Conventional Dosage 
Forms: 
    Drugs are almost never administered alone but rather in the form 
of dosage forms that generally consist of a drug (or drugs) together 
with a varying number of other substances (called excipients). 
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Excipients are added to the formulation in order to facilitate the 
preparation, patient acceptability and functioning of the dosage 
form as a drug delivery system. Excipients include disintegrating 
agents, diluents lubricants, suspending agents, emulsifying agents, 
flavoring agents, coloring agents, chemical stabilizers etc. 
Although historically excipients were considered to be inerts in 
that they themselves should exert no therapeutic or biological 
action, or modify the biological action of the drug present in the 
dosage form, they are now regarded as having the ability to 
influence the rate and/or extent of absorption of the drug. For 
instance, the potential influence of excipients on drug 
bioavailability has already been illustrated by virtue of the 
formation of poorly soluble, non – absorbable drug – excipient 
complexes between tetracyclines and dicalcium phosphate, 
amphetamine and sodium carboxymethylcellulose, and 
phenopbarbitone and polyethylene glycol 4000. (3) 
 
 
Ciprofloxacin 
 
Figure (1-2) Structure of Ciprofloxacin 
 
 
 
Figure (1-3) 3D Structure of Ciprofloxacin 
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1.1.13. Fluoroquinolones: 
   Quinolone antibacterial drugs have been in use since 1964, when 
nalidixic acid was released. Oxolinic and cinoxacin were 
introduced somewhat later. These drugs have fallen into disuse 
because of their limited antibacterial spectra, and resistance to 
them rapidly develops. 
   The introduction of 6-fluoro and 7-(1-piperazinyl) group 
expanded the spectrum, increased potency and appears to have 
prevented the development of plasmid-mediated resistance. The 
fluoroquinolones are bacteriostatic at low and bactericidal at high 
concentrations. 
    They are highly active against most gram-negative pathogens, 
including Ps aeruginosa and the Enterobacteriacea. Staph aureus 
and epidermidis, coagulase-negative staphylococci, Legionella 
myobacteria, and Chlamydia have intermediate sensitivity. 
Streptococci are only moderately susceptible to ciprofloxacin, 
ofloxacin and levofloxacin, while norfloxacin and enxacin are even 
less active. The newest approved fluoroquinolones (levofloxacin, 
sparfloxacin, grepafloxaxin and trovafloxacin) have improved 
activity against Strep. pneumoniae and some gram-negative 
bacteria resistant to older fluoroquinolones. Trovafloxacin has the 
broadest spectrum and best overall activity including better activity 
against anaerobes. Enterococci require very high concentrations. 
The drugs inhibit DNA gyrase (topoisomerase II), which results in 
abnormal linkage between opened DNA and the gyrase. Negative 
supercoiling (absent in mammalian nuclei) is impaired, so protein 
synthesis is prevented. Moderate, chromosomal-mediated 
resistance among strains of Psudomonas occurs clinically in cystic 
fibrosis patients. Resistance to one fluoroquinolone usually confers 
resistance to all other quinolones but not to other classes of 
antimicrobial drugs. 
   Fluoroquinolones are used to treat upper and lower respiratory 
infections, gonorrhea, bacterial gastroenteritis, skin and soft tissue 
infections and both uncomplicated and complicated UTIs 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϭϴ 
 
especially those caused by gram-negative bacteria. In general, 
success is greater against gram-negative than gram-positive 
infections. 
     Adverse effects are usually mild and transient. They include GI 
disturbances (nausea, vomiting, diarrhea, dyspepsia, flatulence, 
constipation, heartburn, abdominal discomfort; 2 to 8%), CNS 
symptoms (headache, restlessness, malaise, dizziness, tremor, 
insomnia, nightmares, depression, paresthesia, visual convulsion; 
rare hallucinations, phobias, manic excitement, confusion; 0.5 to 
6%), hematologic pertumentation rate; 1.5 to photosensitivity 
(especially severe with sparfoxacin), arthopathy in growing 
children, increased likelihood of tendon ruptures (especially 
Achilles in adults) and arthralgias. Prolongation of QT interval 
occurs with some new fluoroquinolones. Suprainfection may 
occurs. Some fluoroquinolones prolong the half-life of 
theophytline; other drug interactions undoubtedly will be 
discovered. Erosion of cartilage occurs in young animals so the 
fluoroquinolones are not recommended for use in children under 
18yr or pregnant or nursing women. Fluoroquinolones are all 
effective orally but also may be administrated parenterally. They 
have large volumes of distribution and reach therapeutic 
concentrations in most tissues. They have long half - lives and may 
be administered only once or twice a day (5) . 
1.1.13.1. Preparation: 
    From 3-chloro-4- fluoroaniline by condensation with diethyl 
ethoxymethylenemalonate to form the imine which is thermally 
cyclized to ethyl 7-chloro-6-fluoro-4-hydroxyquinoline-3-
carboxylate. N-alkylation with cyclopropyl iodide followed by 
neuclephilic displacement 7-chloro group by N-methylpiperazine 
and hydrolysis of the ester affords the product (5).  
1.1.13.2. Description:  
 Pale-yellow crystals; a mphoteric; pKa 6, 8.8. 
 Solubility, 1g in 25mL water. 
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Comments, a fluoroquinolone (see the general statement). It is 
approved for use in the treatment of bone and joint infections, 
infectious diarrhea (by Shigella or Campylobacter), lower 
respiratory tract infections, skin infection and urinary tract 
infection. It is the drug of choice for the treatment of infections by 
Campylobacter jejuni. In addition, it is an unlabeled but 
authoritatively alternative drug for the treatment of gonorrhea and 
salmonella and yersinia infections. The adverse effects are those of 
fluoroquinolones in general. The overall, obviously drug-related 
incidence is 7.3%. Discontinuation is required in about 3.5% of 
cases.The oral bioavailability is about 70 to 80%. A dose of 0.5 g 
yields a plasma concentration 12 hrs after administration of about 
0.2 g/mL.Urinary excretion accounts for the elimination of 40 to 
50% of an oral dose. Twenty to 35% is eliminated in the feces. 
There is hepatic biotransformation of four known metabolites, 
which accounts for 15% of dose. The half-life is about 4 hrs (3). 
1.1.14. Definition of Ciprofloxacin: 
    Systemic (IUPAC) name 
1-cyclopropyl -6-fluoro-7- piperazin -1-ylquinoline-3-carboxylic 
acid 
Identifiers: 
Gas number  8571-33-1 
Solubility                   1 gm in 25 ml  
Chemical data 
Formula    C17H18FN3O3 
Mol. mass   331.346 
Pharmacokinetic data: 
Bioavailability  69% [1] 
Metabolism  Hepatic, including CYP1A2 
Half life   4 hours 
Excretion   renal 
Therapeutic considerations: 
Pregnancy cat.  (AU) C (US) 
Legal status  Prescription Only 
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Routes  Oral, intravenous, topical (ear drops, eye drops)  (5) 
Ciprofloxacin (INN) is a synthetic Chemotherapeutic agent used to 
treat severe and life threatening bacterial infections. Ciprofloxacin 
is commonly referred to as a fluoroquinolone (or quinolone) drug 
and is amember of the fuoroquinolone class of antibacterials. 
Ciprofloxacin is marketed worldwide; with well over three 
hundred different brand names. 
Ciprofloxacin is marketed in the United States, Canada and the UK 
as: Ciloxan, Cipro, Cipro XR, Cipro XL Ciproxin and most 
recently, Porquin (Synonms; Ciprofloxacin Hydrochloride). In 
Sudan it is available over the counter and marketed under many 
names. Additionally Ciprofloxacin is available as a generic drug 
under a variety of different brand names and is also available for 
limited use in veterinary medicine. 
Ciprofloxacin was first patented in 1983 by Bayer A.G. and 
subsequently approved by the United States Food and Drug 
Administration (FDA) in 1987to treat severe and life threatening 
bacterial infections. 
  The licensed uses for ciprofloxacin in the United States are quite 
limited as ciprofloxacin is to be considered a drug of last resort 
when all other antibiotics have failed. These consist of ten 
approved uses in the adult population and to approved uses in the 
pediatric population, as well as a variety of veterinary uses (as 
documented within the package inserts). Any other use is to be 
considered off label since not been approved by the FDA. 
Ciprofloxacin interacts with a number of other drugs, a number of 
herbal and natural supplements, and certain thyroid medications. (6) 
1.1.15. Chemical Nature: 
   Ciprofloxacin is 1-cyclpropyl-6-fluro-1, 4-dihydro-4-oxo-7-(1-
piperazinyl)-3-quionlincarboxylic acid. Its empirical formula is 
C17H18FN3O3 and its molecular weight is 331.4. It is a faintly 
yellowish to light yellow crystalline substance. 
Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is the 
monohydrochloride monohydrate slat of 1-cyclopropyl-6-fluoro-1, 
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4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. It is 
faintly yellowish to light yellow crystalline substance with a 
molecular weight of 385.8. Its empirical formula is 
C17H18FN3O3 HCl H2O. 
   There are a number of the endogenous compounds that have 
been reported to be affected by Ciprofloxacin as inhibitors, 
alteraters and depletory. (7) 
1.1.15.1. Pharmacokinetics: 
    The pharmacokinetics of ciprofloxacin is linear over the dose 
range of 200 to 400 mg administrated intravenously. Comparison 
of the pharmacokinetic parameters following the 1st and 5th I.V. 
dose on a q 12 h regimen indicates no evidence of drug 
accumulation. The absolute bioavailability of oral ciprofloxacin is 
within a range of 70 – 80% with no substantial loss by first pass 
metabolism. An intravenous infusion of 400mg ciprofloxacin given 
over 60 minutes every 12 hours has been shown to produced by an 
area under the serum concentration time curve (AUC) equivalent 
to that produced by 500-mg oral dose given every 12 hours. An 
intravenous infusion of 400mg ciprofloxacin given over 60 
minutes every 8 hours has been shown to produce an AUC at 
steady – state equivalent to that produced by a 750-mg oral dose 
given every 12 hours. A 400-mg I.V. dose results in a Cmax 
similar to that observed with a 750-mg oral dose. An infusion of 
200 mg ciprofloxacin given every 12 hours produces an AUC 
equivalent to that produced by a 250-mg oral dose given every 12 
hours. 
  Ciprofloxacin should only be administrated as described within 
the Dosage Guidelines table found within the most current package 
insert. The status of the patient’s renal function and hepatic 
function must also be taken into consideration to avoid an 
accumulation that may lead to a fatal drug overdose. Ciprofloxacin 
is eliminated primarily by renal excretion. However, the drug is 
also metabolized and partially cleared through the liver and the 
intestine. Modification of the dosage is recommended using the 
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table found within the package insert for those with impaired liver 
or kidney function. (Particularly for patients with severe renal 
dysfunction).  However, since the drug is known to be substantially 
excreted by the kidneys, the risk of toxic reactions to this drug may 
be greater in patients with impaired renal function. The duration of 
treatment depends upon the severity of infection and the usual 
duration is 7 to 14 days. 
Notice: The patient’s serum levels should be monitored during 
therapy to avoid a drug overdose. (8) 
1.1.15.2. Susceptible Bacteria: 
      Aerobic gram-positive microorganisms 
· Enterococcus feacalis (Many strains are only moderately 
susceptible). 
· Staphylococcus aureus (Methicillin-susceptible strain only). 
· Staphylococcus epidermidis (Methicillin-susceptible strain 
only). 
· Streptococcus pneumoniae (Penicillin-susceptible strain only). 
· Streptococcus pyogenes. 
    Aerobic gram-negative microorganisms 
· Campylobacter jejuni 
· Proteus mirabilis 
· Citrobacter diversus 
· Proteus vulagris 
· Citrobacter freundii 
· Providencia rettgeri 
· Enterobacter cloacae 
· Providencia stuartii 
· Escherichia coli 
· Pseudomonas aeruginosa  
· Haemophilus influenzae 
· Salmonella typhi 
· Haemophilus parainfluenzae 
· Serratia marcescens 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
Ϯϯ 
 
· Klebsiella pneumoniae 
· Shigella boydii 
· Moraxella catarralis 
· Shigella sysenteriae 
· Morganella morganii 
· Shigella flexneri 
· Neisseria gonorrhoeae 
· Shigella sonnei 
   A class action had been filed against Bayer AG on behalf of 
employee of the Brentwood Post Office in Washington, D.C., and 
workers at the U.S. Capitol, along with employees of American 
Media, Inc. in Florida and postal workers in general who allege 
that they have suffered serious side effects from taking the 
antibiotic ciprofloxacin in the aftermath of the anthrax attacks in 
2001. The action alleged that Bayer failed to warn class members 
of the potential side effects of the drug, thereby violating the 
Pennsylvania Unfair Trade Practices and Consumer. (7) 
1.1.15.3. Risk / Benefit Assessment: 
   The benefits of ciprofloxacin therapy have also been widely 
disputed. There are major discrepancies between the promoted 
image and the clinically interpreted usefulness of ciprofloxacin, 
and what has been reported within the leading medical journals or 
the results of independent double blind studies, in a number of 
instances. (7) 
1.1.15.4. Chronic Bacterial Prostatitis:  
   Prostatitis has been termed “the waste basket of clinical 
ignorance” by prominent Standford University Urologist Dr. 
Thomas Stamey.  
   Campbell’s Urology, the urologist’s most authoritative reference 
text, identifies only about 5% of all patients with prostatitis as 
having bacterial prostatitis which can be “cured” at least in the 
short term by antibiotics. In other words, 95% of men with 
prostatitis have little hope for a cure with antibiotics alone since 
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thry don’t actually have any identifiable bacterial infection. Within 
a 2003 study involving the use of fluoroquinolones to treat Chronic 
Bacterial Prostatitis it was found that the level of improvement was 
no different from that associated with placebo. Within a 2004 
randomized, double – blind trial involving ciprofloxacin 
specifically, it was found that ciprofloxacin “did not substantially 
reduce symptoms in men with long-standing CP/CPPS who had at 
least moderate symptoms.” Chronic pelvic pain (category IIIB) is 
often misdiagnosed as chronic prostatitis and needlessly treated 
with ciprofloxacin. Within a Bulgarian study, where by definition 
all patients had negative microbiological results, we see a 65% 
adverse drug reaction rate for patients treated with ciprofloxacin in 
comparison to a 9% rate for the placebo patients. This was 
combined with a higher cure rate (69% v 53%) found within the 
placebo group. The authors stated that “The results of our study 
show that antibiotics have an unacceptably high rate of adverse 
side effects as well as a statistically insignificant improvement 
over placebo”. (7) 
1.1.15.5. Infectious Diarrhea: 
   A Clostridium difficile infection is the principal cause of 
ciprofloxacin – associated diarrhea and pseudo membranous 
colitis. In June 2007 the FDA changed the package insert for 
ciprofloxacin to include the warning that the Clostridium difficile 
associated diarrhea (CDAD) is associated with the use of 
ciprofloxacin. As such the efficacy of ciprofloxacin to treat 
infectious diarrhea would be called into question (7). 
1.1.15.6. Generic Equivalents: 
   On October 24, 2001, The Prescription filed suit to dissolve an 
agreement between Bayer, Barr Laboratories, and to other generic 
drug companies that it claimed was blocking access to adequate 
supplies and cheaper, generic versions of ciprofloxacin. The 
plaintiffs charged that Bayer Corporation, a unit of Bayer AG, had 
unlawfully paid three of its competitors – Barr Laboratories, 
Rugby, and Hoechst-Marion Roussel – a total of $200 million to 
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prevent cheaper, (generic versions) of ciprofloxacin being brought 
to the market, as well as manipulating the price and supply of 
ciprofloxacin. Numerous other consumer advocacy groups joined 
this lawsuit. On October 15,2008, five years after Bayer’s patent 
had expired, the United States District Court for the Eastern 
District of New York granted Bayer’s and the generic defendant’s 
motion for summary judgment, holding that any anti – competitive 
effects caused by the settlement agreements between Bayer and 
thus could not be redressed by federal antitrust law. In effect 
upholding Bayer’s agreement to pay – Barr Laboratories, Rugby, 
and Hoechst – Marion Roussel – a total of $200 million to prevent 
the marketing a generic equivalent of ciprofloxacin. (9) 
1.1.15.7. Antimicrobial Resistance: 
   There are three known mechanisms of resistance. Some type of 
efflux pumps can act to decrease intracellular quinolone 
concentration. In gram-negative bacteria, plasmid-mediated 
resistance genes produce proteins that can bind to DNA gyrase, 
protecting it from the action of quinolones. 
   Finally, mutations at key sites in DNA gyrase of Topoisomerase 
can decrease their binding affinity to quinolones, decreasing the 
drug’s effectiveness. (9) 
1.1.15.8. Adverse Effects: 
    Fluoroquinolones are generally well tolerated with most side 
effects being mild and serious adverse effects occurring rarely. 
Some of the serious adverse effects which occur more commonly 
with fluoroquinolones than with other antibiotic drug classes 
include central nervous system (CNS) side effects and tendon 
toxicity. Unusual adverse reactions include psychosis and chorea 
(involuntary muscle movements). The currently marketed 
quinolones have safetyprofiles similar to that of other antimicrobial 
classes. Phototoxicity, neurological symptoms, impaired colour 
vision, exanthema, abdominal pain, malaise, drug fever, peripheral 
neuropathy, dysaesthesia and eosionphilia have been observed as 
adverse effects of ciprofloxacin. 
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  The serious events may occur with therapeutic or with acute 
overdose. At therapeutic doses they include: central nervous 
system toxicity, cardiovascular toxicity, tendon/articular toxicity, 
and rarely hepatic toxicity. Events that may occur in acute 
overdose are rare and include: renal failure and seizure. Children 
and the elderly are at greater risk. Adverse reactions may manifest 
during, as well as after fluoroquinolones therapy. Unusual but 
potentially serious adverse reactions occur as a result of 
ciprofloxacin administration bone marrow depression, interstitial 
nephritis and hemolytic anemia occur during ciprofloxacin use. 
    Pseudotumor cerebri, commonly known as idiopathic 
intracranial hypertension (IIH), also referred to as increased 
intracranial pressure, has been reported to occur as a serious but 
isolated adverse reaction to ciprofloxacin. An unusual case of 
seizures has been reported with ciprofloxacin ear drops in an 
elderly lady (7). 
1.1.15.9. Overdose: 
   In the event of acute over dosage, case of reversible renal 
toxicity has been reported. The stomach should be emptied by 
inducing vomiting or by gastric lavage. The patient should be 
carefully observed and given supportive treatment, including 
monitoring of renal function and administration of magnesium, 
aluminum, or calcium containing antacids which can reduce the 
absorption of ciprofloxacin. Adequate hydration must be 
maintained. Only a small amount of ciprofloxacin (<10%) is 
removed from the body after hemodialysis or peritoneal dialysis. (7) 
1.1.16. Taste Masking Technologies: 
    Taste is the ability to respond to dissolved molecules and ions-
(gate keeper to the body). Human have around 10,000 taste bud 
which appeared in fetus at about three months. A single taste bud 
contain  50 – 100 taste cells each taste cells receptors on it is apical 
surface.these are transmembrane proteins which binds to the 
molecules and ions- that give rise to the four primary taste 
sensations namely - salty, sour, sweet and bitter.(22) 
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   Recently, a fifth basic taste umami has been discoved. The 
umami is the taste of certain amino acids. There is often a 
correlation between the chemical structure of a compound and its 
taste. Low molecular weight salts tend to taste salty where as high 
molecular weight salts more towards bitterness. Nitrogen 
containing compounds, such as alkaloids tend to be quite bitter. 
Organic compounds containing hydroxide groups tend to be 
increasingly sweet as the number of OH increases. (23)  
    So major taste masking efforts are required before bitter drugs 
become acceptable for market trials. Major masking technologies 
are based on the reduction of solubility of the drug in the saliva so 
the drug concentration in saliva will remain below taste threshold 
value (is a minimum concentration of substance that evoks 
perception of a taste). The desire for improved palatability of 
formulations has prompted the development of various new 
technologies for taste abatement many of this technologies have 
been successfully commercialized. But the ideal solution of taste 
masking would be the discovery of universal inhibitor of bitter 
taste of all drugs. (24)  
1.1.16.1. Techniques to Mask Bitterness: 
a) Taste masking with flavors and sweeteners: 
    This technique is the simplest approach for taste masking. But 
this approach is not very successful for highly bitter drugs. Thus 
artificial sweet and flavors are generally being used along with 
other taste masking techniques to improve the efficiency of these 
techniques. Saccharin is most sweetness of commonly used 
sweeteners. It is equal 450 times a unit of sucrose. However, it 
suffers from unpleasant after taste. Vanilla is very stable and 
masks effect of bitterness. (24)  
b) Microencapsulation: 
    Is a process by which very tiny droplets or particles of liquid or 
solid material are surrounded or coated with a film or polymeric 
     material. (25) 
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 Advantages:  
· Taste masking can be achieved with desirable fast or controlled 
drug release 
· Bitter liquids may be coated to convert them to solid particles 
· The coated bitter particles can adapt to a wide variety of dosage 
forms and product application.(25) 
c) Taste masking by ion exchange resins: 
  Ion exchange resins are synthetic organic polymers consisting of 
a hydrocarbon network to which ionisable groups are attached and 
they have the ability to exchange their labile ions present in the 
solution with which they are in contact.(26) (27)  
d) Taste masking by formulation of inclusion complexes: 
   Inclusion complexes are host- guest in which complexion agent 
act as host and provide cavities in which foreign guest molece 
may fit e.g. Cyclodextrin. The complexion agent masking bitter 
taste of drug by either decreasing its oral solubility on ingestion or 
decreasing the amount of drug particles exposed to taste buds.(28) 
e) Taste mask by granulation: 
   Granulation is a common processing step in the production of 
tablet dosage form. This step can be exploited as a means for taste 
masking of slightly bitter tasting drugs. Some saliva insoluble 
polymers can also act as binding agent, granules prepared from 
these polymers show less solubility in saliva and thus taste could 
be masked by decreasing effective surface area of bitter substance 
in contact with the tongue e.g. guar.(12) 
f) Taste masking by adsorption:  
        Adsorption involves preparing a solution of the drug and 
mixing it with an insoluble powder that will absorb the drug, 
removing the solvent, drying the resultant powder, and then using 
this dried adsorbents in the preparation of the final dosage form 
e.g. veegum, pentonite, silica gel and silicate, example of drug 
loperamide adsorbed on a veegum.(31) 
g) Taste masking by prodrug approach: 
A prodrug is chemically modified inert drug precursor which 
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opens bio transformation that liberates the pharmaceutically active 
parent compound. Example antibiotic Chloramphenicol 
palmitate.(32) 
h) Solid dispersion method:       
  Define as dispersion of one or more active ingredients in an inert 
carrier or matrix at solid state prepared by melting (fusion) solvent 
or melting solvent method carriers used in solid dispersion system 
include polyethylene glycols. (28) 
i) Molecular complexes of drug with other chemicals: 
    The solubility and adsorption of drug can be modified by 
formation of molecular complexes. Consequently lowering drug 
solubility through molecular complex formation can decrease 
bitterness of drug. (28)  
j) Taste masking by bitterness inhibiters: 
     Can be use in controlled release delivery of pharmaceuticals if 
the system is stable. (33)-(34) 
k) Taste masking by gelatin: 
    Water insoluble gelatin on the surface of tablet containing bitter 
drug can be used for taste masking. Sodium alginate has the 
ability to cause water insoluble gelatin in presence of bivalent 
metal ions. (35) 
l) Miscelleneous taste masking approach: 
· By effervescent agents: 
Effervescent agents have been shown to be useful and 
advantageous for oral administration of drugs and have been 
employed for use as taste masking agent for dosage forms that are 
not dissolved in water prior to administration. Chewing gum 
composition of bitter medicament was formulated to supply the 
medicament to oral cavity for local application or for buccal 
absorption. It comprises chewing base, an orally administrable 
medicament, a taste masking generator of carbon dioxide, and 
optionally a taste bud desensitizing composition (e.g. oral 
anaesthetic such as benzocaine) and other non active material such 
as sweeteners, flavoring components and fillers. Recently, 
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effervescent tablets of fentanyl and brochlorperazine were 
developed to supply these drugs to the oral cavity for buccl, 
sublingual, and gingival absorption, The formulation contains the 
drug in combination with effervescent agent to promote their 
absorption in the GIT, to mask their bitter taste and to enhance 
swallow. (36) 
· Rheological modification: 
   Increasing the viscosity with rheological modifier such as gums 
or carbohydrates can lower the diffusion of bitter substances from 
the saliva to the taste buds. The antidepressant drug mirtazapine is 
formulated as an aqueous suspension using methonine (stabilizer) 
and maltitol (thickening agent). Beside masking unpleasant taste of 
the drug it also inhibits its undesirable local anaesthetic effect.(37)(40)   
· Continuous multipurpose melt (CMT technology): 
  This method was developed for the continuous granulation and 
coating of pharmacologically active substances. It was concluded 
that this method could be successfully applied for taste masking of 
bitter drugs.(42)  
1.1.16.2. Sensory Evaluation: 
· Panel testing (43) 
· Measurement of frog taste nerve response (44)  
· Multichannel taste sensor / magic tongue (45) (46) 
· Spectrophotometric method (47) 
    In this research the guideline was taken from the above and to 
make mask of the bitterness of the ciprofloxacin.  
1.1.17. Packaging of Effervescent Tablet: 
    Metals and glass are intended for packaging effervescent tablet 
however as the price of tin constantly varies, more – collapsible 
aluminum tubes are being used. Lead tubes tend to have been used 
little in the industry. Tin tubes can be coated with wax or with 
vinyl lining. Effervescent tablet must be well closed to prevent it 
from humidity. (48)      
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1.2. Literature Review: 
    A comparison study was done in Jose Nigeria for post-market 
ciprofloxacin in 2009 by using dissolution method as fundamental 
method to determine bioequivalence of ciprofloxacin. 
     In Omdurman Islamic University faculty of pharmacy another 
research in formulation of ciprofloxacin was carried out. 
    Ciprofloxacin was formulated as effervescent in high lotion in 
University of Cairo and in Poston 2007 and this give guideline to 
make effervescent tablets.  
     In a 1986 issue of the Journal of Antimicrobial Chemotherapy, 
a leading article on quinolones in chest infections concludes that 
there is little reason for optimism about the role of quinolones in 
chest infections mainly because of problems with resistance. 
Recurrence, and reinfection with Pseudomonas aerufinosa and S. 
pneumonia.  
    Antibiotics do not improve sinusitis symptoms a number of 
studies have shown. Primary care physicians (family doctors) 
commonly prescribe cirpfloxacin to treat acute maxillary sinusitis 
(inflamed membrances of the sinuses), although there is no 
evidence that this approach is effective. A report in the British 
medical Journal the Lancet found that antibiotics did nothing more 
than the placebos used as the control. 
    Only about 5 – 10% of bronchitis cases are caused by a bacterial 
infection. Most cases of bronchitis are caused by a viral infection 
and are “self-limited” and resolve themselves in a few weeks. (6) 
1.2.1. Licensed Uses: 
    Ciprofloxacin is sold over the counter in Sudan. Ciprofloxacin is 
the generic name in this country. 
The licensed uses for ciprofloxacin in the United States are as 
follows: 
    Oral and I.V. fluoroquinolones are not licensed by the FDA for 
use in children due to the risk of permanent injury to the 
musculoskeletal system, with two exceptions as outlined below. 
Within the studies submitted in response to a Pediatric Written 
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Request (Ciprofloxacin, circa 2004) the rate of atrophy was 
reported to be 9.3% at one month and 13.6% at one year. As such 
the pediatric use of ciprofloxacin is restricted to proven 
complicated urinary tract infections and pyelonephritis due to E. 
coli and inhalation anthrax. Although alleged to be effective, 
ciprofloxacin is not to be considered a first line agent for inhalation 
anthrax in the pediatric population due to severe adverse reactions 
involving the musculoskeletal system and other serious adverse 
reactions, including fatalities. The CDC revoked its 
recommendation regarding the use of ciprofloxacin as a first line 
agent in treating anthrax due to the unacceptable risk documented 
within the Antimicrobial Postexposure Prophylaxis for Anthrax 
study (aka Cipro 60 day study). However, the fluoroquinolones are 
licensed to treat lower respiratory infections in children with cystic 
fibrosis in the UK. Prescribing a fluoroquinolones to treat an 
unapproved use within the pediatric (as well as the adult 
population) exposes the treating physician to the risk of being sued 
for malpractice should the treating physician fail to both warn the 
patient of this fact, as well as the risks of any adverse drug 
reactions the patient may experience. 
In the adult population ciprofloxacin is limited to the treatment of 
proven serious and life threatening bacterial infections such as: 
· Urinary Tract Infections. 
· Acute Uncomplicated Cystitis in females. 
· Lower Respiratory Tract Infections. 
· Acute Sinusitis. 
· Skin and Skin Structure Infections. 
· Bone and Joint Infections. 
· Infectious Diarrhea. 
· Typhoid Fever (Enteric Fever) caused by Salmonella typhi. 
· Uncomplicated cervical and urethra gonorrhea (due to N. 
gonorrhea) mainly in Sudan. However this indication is no 
longer effective due to bacterial resistance. 
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As well as in combination with other specific drugs: 
· Complicated intra-abdominal infections (in combination with 
metronidazole); 
· Empirical therapy for febrile neutropenic patients (in 
combination with piperacillin). 
In the pediatric population ciprofloxacin is limited to the treatment 
of proven serious and life threatening bacterial infections such as: 
· Complicated Urinary Tract Infections and Pyelonephritis due 
to Eschericha coli. 
· Inhalational Anthrax (post-exposure).(6) 
Ciprofloxacin is not a drug of first choice in the treatment of 
presumed or confirmed pneumonia secondary to Streptococcus 
pneumoniae. As such ciprofloxacin is not recommended for 
community acquired pneumonia and other such chest infections. 
Antibiotics such as ciprofloxacin do not improve sinusitis 
symptoms. When prescribed for Community Acquired Pneumonia, 
Chronic Bronchitis, and Acute Bacterial Sinusitis the use of the 
fluoroquinolones class offers no compelling advantages over 
established treatment. Nor does antibiotic treatment help sore 
throats. The use of antibiotics such as ciprofloxacin to treat 
bronchitis is to be considered unnecessary and as such exposes the 
patient to an unacceptable risk of suffering a severe adverse 
reaction. Antibiotics futility against bronochitis had been 
confirmed in 2002. Additionally ciprofloxacin and other 
fluoroquinolones have no effect upon viral infections such as the 
common head cold. 
Note: Ciprofloxacin may be licensed for other uses, or restricted, 
by the various regulatory agencies worldwide. (6) 
1.2.2. Availability: 
    Ciprofloxacin is available as: 
Tablet; Oral containing 250mg, 500mg 0r 750mg ciprofloxacin. 
Prescription  
Solution; IV. Containing 5% 100mL, 250mg/5mL and 10% 
100mL, 500mg/5mL. Prescription 
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Also used in eye and ear drops. Prescreption. (7) 
1.2.3. Mode of Action: 
    Ciprofloxacin is a broad – spectrum antibiotic that is active 
against both Gram-positive and Gram-negative bacteria. It 
functions by inhibiting DNA gyrase, a type  topoisomerase, and 
topoisomerease iv, which is an enzyme necessary to separate 
replicated DNA, therapy inhibiting cell division. 
The fluoroquinolones interfere with DNA replication by inhibiting 
an enzyme complex called DNA gyrase. This can also affect 
mammalian cell replication. In particular, some congeners of this 
drug family display high activity not only against bacterial 
topoisomerase, but also against eukaryotic topoisomerease and are 
toxic to mammalian cells in culture, its mechanism of cytotoxic 
action is not known. Quinolone induced DNA damage was first 
reported in 1986. (6) 
      Recent studies have demonstrated a correlation between 
mammalian cell cytotoxicity of the quionlones and the induction of 
micronuclei. As such some fluoroquinolones may cause injury to 
the chromosome of eukaryotic cells.There continues to be 
considerable debate as to whether or not this DNA damage is to be 
considered one of the mechanisms of action concerning the severe 
and non abating adverse reactions experienced by some patients 
following fluoroquinolones therapy. (7) 
1.2.4. Contra Indications: 
    As noted above, under licensed use, ciprofloxacin is also now 
considered to be contraindicated for the treatment of certain 
sexually transmitted diseases by some experts due to bacterial 
resistance. “Co-administration of ciprofloxacin with other drugs 
primarily metabolized by CYPIA2 results in increased plasma 
concentrations of these drugs and could lead to clinically 
significant adverse events of the co-administered drug.” 
“Concomitant administration with trizanidine is contraindicated” 
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“Ciprofloxacin is contraindicated in persons with a history of 
hypersensitivity to ciprofloxacin, any member of the quinolone 
class of antimicrobial agents, or any of the product components”. 
“Local I.V. site reactions are more frequent if the infusion time is 
30 minutes or less. These may appear as local skin reactions which 
resolve rapidly upon completion of the infusion. Subsequent 
intravenous administration is not contraindicated unless the 
reactions recur or worsen.” (7) 
    Due to growing prevalence of antibiotic resistance to the 
fluoroquinolones in Southeast Asia, the use of Ciprofloxacin in 
patients who have been to Southeast Asia is increasingly being 
contraindicated. Ciprofloxacin is also considered to be 
contraindicated within the pediatric population (except for the 
indications outlined under licensed use above), pregnancy, nursing 
mothers, and in patients with epilepsy or other seizure disorders. (7) 
   Fluoroquinolones are not licensed by the FDA for use in children 
due to the risk of fatalities as well as permanent injury to the 
musculoskeletal system, with two exceptions. Ciprofloxacin is 
being licensed for the treatment of Complicated Urinary Tract 
Infections and Pyelonephritis due to E.coli and Inhalation Anthrax 
(post-exposure).  To recent pediatric studies involving the use of 
levofloxacin indicates that the pediatric patient has a greater (> 
50%) chance of experiencing one or more adverse reactions. 
1.2.5. Interactions: 
    The toxicity of drugs that are metabolized by the cytochrome 
P450 system is enhanced by concomitant use of some quinolones. 
Coadministration may dangerously increase Coumadin warfarin 
activity. They may also interact with the GABA receptor ad cause 
neurological symptoms; this effect is augmented by certain non-
steroid anti-inflammatory drugs.Quercetin, a flavonoid 
occasionally used as a dietary supplement, may interact with 
fluoroquinolones, as quercetin competitively binds to bacterial 
DNA gyrase. Some foods such as garlic and apples contain high 
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levels of quercetin; whether this inhibits or enhances the effect of 
fluoroquinolones is not entirely clear.  
    Ciprofloxacin can reduce phenytoin plasma level which may in 
some cases result in seizures. Administration of ciprofloxacin, with 
antacids, sucralfate or minerals may substantially decrease the 
absorption of ciprofloxacin, resulting in serum and urine levels 
considerably lower than desired. The fluoroquinolones have also 
been showed to interfere with the absorption of levothyroxine, 
resulting in unexplained hypothyroidism.  
   The use of (NSAIDs) while undergoing fluoroquinolone therapy 
is contra-indicated due to the risk of severe CNS adverse reactions. 
Some quinolones exert an inhibitory effect on the cytochrome P-
450 system, thereby reducing theophylline clearance and 
increasing theophylline blood levels. Coadministration of certain 
fluoroquinolones and other drugs primarily metabolized by 
CYPIA2 (e.g. theophylline, methylxanthines, tizanidine) results in 
increased plasma concentrations and could lead to clinically 
significant side effects of the coadministrated drug.  
   Renal tubular transport of methotrexate may be inhibited by 
concomitant administration of ciprofloxacin. Probenecid interferes 
with renal tubular secretion of ciprofloxacin and produces an 
increase in the level of ciprofloxacin in serum. (7)    
1.2.6. Scripting Abuse and Bacterial Resistance: 
     Resistance to ciprofloxacin and other fluoroquinolones may 
evolve rapidly, even during a course of treatment. Numerous 
pathogens, including Staphylococcus aureus, enterococci, and 
Streptococcus pyogenes now exhibit resistance worldwide. 
Widespread veterinary usage of the fluoroquinolones, particularly 
in Europe, has been implicated. The ever increasing bacterial 
resistance to ciprofloxacin, (which is a major concern), may very 
well threaten its future viability to treat serious and life threatening 
bacterial infections. Years ago the FDA had added warning 
regarding the proper use of this drug within the package insets to 
combat such scripting abuse.  Adverting physicians that 
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ciprofloxacin “should be used only to treat or prevent infections 
that are proven or strongly suspected to be caused by susceptible 
bacteria”. Normally ciprofloxacin should only be used in patients 
who have failed at least one prior therapy. Reserved for the use in 
patients who are seriously ill and may soon require immediate 
hospitalization. Though considered to be a very important and 
necessary drug required to treat severe and life threatening 
bacterial infections, the associated scripting abuse of ciprofloxacin 
remains unchecked, which has contributed Protection Laws. 
According to the allegations within the complaint, exposed 
individuals were not informed of the true safety profile of 
Ciprofloxacin, the high rate of adverse events associated with its 
use or the availability of safer and equally effective alternative 
drugs. The complaint further alleged that, as a result of taking 
Cipro, individuals may suffer severe and debilitating injuries. The 
action sought funding for a medical monitoring program and 
compensatory damages for those workers who have suffered side 
effects. In 2004, the law firm of Goodell, DeVries, Leech & Dann, 
LLP were retained as national counsel in this litigation. The class 
action was defeated and the litigation abandoned by plaintiffs. A 
similar action had been filed in New Jersey that covers New Jersey 
postal workers. Final disposition of that lawsuit is unknown. 
Following the addition of the Black Box Warning in 2008, 
regarding tendon damage, a significant number of product liability 
law firms began soliciting clients who have suffered a spontaneous 
tendon rupture following fluoroquinolone therapy. (6) 
   As previously stated the use of ciprofloxacin to treat this disease 
has been severely compromised by bacterial resistance.As such 
most of the approved uses for ciprofloxacin have shown either lack 
of reasonal efficacy within a number of independent studies, or has 
been severely compromised by growing bacterial resistance. 
Applying a reasonable risk/benefit assessment to the use of 
ciprofloxacin there would be very few cases where the use of a 
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fluoroquinolone drug, such as ciprofloxacin, should be considered 
by the treating physician to be a first line agent. 
   Ciprofloxacin has been associated with significant collateral 
system toxicity during therapy; as such the potential for benefit 
may not out weight the proven risk when there is a safer alternative 
available to the treating physician. (6) 
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. OBJECTIVES 
 
2.1. General Objectives: 
    To formulate ciprofloxacin hydrochloride as an effervescent 
tablet by suitable method and make comparative study with five 
local brands. 
2.2. Specific Objectives: 
· To make full comparative post-market study and monitoring of 
five brands of ciprofloxacin HCl (500 mg) coated tablets. 
· To develop an effective ciprofloxacin HCl tablets which will 
enhance resistance reduction of this drug. 
· To select suitable method for formulation of effervescent 
ciprofloxacin HCl.  
· To give confidence in the local products.           
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  METHODOLOGY 
3.1. Materials: 
3.1.1. Chemicals and Reagents: 
Code   Brand Name     Dosage form      Country of origin 
A           Bactiflox           Tablet                  Switzerland  
B           Amiciprox         Tablet                     Sudan 
C           Ciproquin          Tablet                      India 
D           Safloxin            Tablet                      Sudan 
E           Epoflox             Tablet                      Sudan 
Ciprofloxacin HCl powder                    Pharmaceutical laboratory        
University of Khartoum                     
Citric acid and Tartaric acid                   Pharmaceutical Laboratory 
                                                         University of Khartoum 
Sodium bicarbonate                             lab chemic-India   
Saccharin                                              lab chemic-India 
Vanillin                                                Wafrapharma, Sudan 
Guar                                                       Pharmaceutical Laboratory  
 University of Khartoum 
Distilled water                                        Pharmaceutical Laboratory   
 University of Khartoum 
Sulfuric acid                                         BDH Ltd, England 
Barium chloride                                   BDH Ltd, England 
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 Hydrochloric acid 0.1N HCl                BDH Ltd, England 
 Normal saline                                      BDH Ltd, England 
Microcrystalline cellulose                       Pharmaceutical Laboratory 
                                                          University of Khartoum    
Polyvinyl pyrollodine                             Pharmaceutical Laboratory 
                                                          University of Khartoum     
 
Magnesium Stearate                               Pharmaceutical Laboratory 
                                                         University of Khartoum    
Lactose                                                    Pharmaceutical Laboratory 
                                                         University of Khartoum      
Talc                                                      lab chemic-India 
Ferric chloride                                      BDH Ltd, England   
3.1.2. Culture Media: 
Mueller Hinton Agar                            Oxoid Ltd, England 
 MacConkey Agar                                    Oxoid Ltd, England  
 Nutrient Agar                                          Oxoid Ltd, England 
3.1.3. Equipment and Instrument: 
Electrical Balance                                   Sartorius, Germany 
Friability Tester Type TA 100                Heusentamm, Germany  
Disintegration Tester                               Heusentamm, Germany    
Hardness Tester Type TBH 210              Heusentamm, Germany  
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Single Punch Tablet Machine                Erweka, Germany 
Dissolution Machine                               Caleva, Germany     
 Autoclave                                               Baired and Tatlock, England 
 Incubator Apparatus                               Baired and Tatlock, England  
 Refrigerator                                            Sudan 
Glassware (e.g. flask, pipette...etc)         Grifffin and George LTD   
 PH Meter Type HI 9812                         Hanna – Instrument UK 
Oven                                                        3K company, Turkey  
Hot Air Oven                                           Labsco, Germany   
U.V Spectrophotometer Model 6505      Janaway Company UK 
Hardness Tester Model THT 500            Caleva, Germany 
3.1.4. Test Control Organisms:  
Clinical Isolates Microorganisms. The following microorganisms were 
used:  
(Salmonella Sp, Staphylo coccus aureus, Escherechia coli). 
 Ǥ͵ʹ. Methods: 
3.2.1. Introduction of Methodology: 
   Five brands of ciprofloxacin 500 mg were randomly collected 
and quality control tests of uniformity of weight, hardness, 
friability, assay, disintegration and dissolution tests were carried 
out with the aim to assess physicochemical properties and their 
quality. The results obtained have been discussed in some details 
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using monographs, the results were also subjected to statistical 
analysis. Also the formulation of the ciprofloxacin HCl ac 
effervescent tablets was carried out by two methods and 
comparison between the two methods was done with fundamental 
tests. (10) 
   (Key word: quality control tests, ciprofloxacin, dissolution, 
dissolution efficiency, weight variation, hardness, friability and 
disintegration). Post-market surveillance or monitoring involves all 
activities undertaken to obtain more data and information about a 
product after it had been granted marketing authorization and made 
available could be employed for product improvement, 
development of standards and regulations. Regulatory agencies 
rely on limited information obtained during clinical trails and to 
some extent scientific literature as guides to granting marketing 
authorization of medicines for public use. It is therefore imperative 
to conduct post-market surveillance to assess the quality. Post-
market monitoring ought not to be one event rather it should be a 
continuous work throughout the shelf life of a drug to include: 
review of product’s condition of approved study; evaluation and 
investigation of reported drug complaints; inspection of 
manufacturer’s processes and procedures for production and 
complaint handling; market surveys, technical and clinical 
documentation; review of product claims/labeling; public access to 
information taken and reported to the regulatory agency (ies); and 
in vitro testing for compliance to standards. In vitro testing or 
quality control of drug is a set of studies or experiments 
undertaken during production (in process) and occasionally ought 
to be undertaken post-production by regulatory testing of drugs in 
the market. This is crucial to protect public health especially in 
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developing countries where counterfeit and substandard drugs have 
become a major challenge to health care services. In Sudan, several 
attempts have been made to combat counterfeit and substandard 
drugs. Counterfeit and substandard medicines are a major cause of 
morbidity, mortality and loss of public confidence in drugs and 
health structures (11).  
3.3. Data Analysis: 
    The uniformity of weight was analyzed statistically by 
calculating percentage deviation from the formula for the different 
five brands beside the fundamental tests that are included in 
official monographs.  
3.4. Experiment Analysis: 
   This research discusses ciprofloxacin formulation, Quality 
Control (physicochemical properties and sensitivity test) by using 
fundamental methods and monographs.  
3.5. Formulation of Tablets: 
     Tablets were prepared by two methods. In the two   
Methods: The ratios of the effervescent ingradients were taken as 
(1:2:3.4) respectively for citric acid: tartaric acid: sodium 
bicarbonate according to the following equation. 
Citric acid: 
 
 
 
 
Tartaric acid: 
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     From the above equations the ratio of effervescent ingredients 
used was (1:2:3.4) for the citric acid tartaric acid: sodium 
bicarbonate (41). 
3.5.1. Wet Granulation: 
     The most widely used and most general method of tablet 
preparation is the Wet Granulation method. Its popularity is due to 
the greater probability that the granulation will meet all the 
physical requirements for the compression of good tablets. Its chief 
disadvantages are the number of separate steps involved as well as 
the time and labor necessary to carry out the procedure, specially 
on a large scale. The steps in the wet method are weighing, mixing, 
granulation, screening, drying, dry screening, lubrication and 
compression. The equipment involved depends on the quantity or 
size of the batch. The active ingredient, diluents, and disintegrant 
are mixed or blended well. (2) 
     Specific amount of ciprofloxacin and saccharin were weighed 
and were divided into two pestles in equal amount and well mixed 
to each one of pestles effervescent base was added Citric and 
Tartaric acid in one and sodium bicarbonate in another one to 
avoid reaction then the binder combination (Guar and Poly vinyl 
pyrollodine) was added slowly after dissolving in a very small 
amount of water and then the mixture was blended continuously to 
make the paste, granulated using mesh (10), and then put in oven 
for drying for twenty hours. The mixture was passed through mesh 
(14) after drying using mesh (14). The micro crystalline cellulose 
when added before granulation used as disintegrant and after 
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granulation as glident. Talc powder and magnesium stearate were 
added as lubricant and glident. Granules were compressed into two 
types one tablet 250 mg (0.25 gm active ingredient) by 20mm die 
and 125 mg (0.125 gm ingredient ) by 13mm die as divided dose.(2)               
3.5.1.1. Calculations: 
Formula (1) (high binder concentration): 
Guar: 1% & PVP: 4% (w/w) 
 Formula (2) (low binder concentration): 
Guar: 0.005% & PVP: 2% (w/w) 
· Guar with poly Vinyl pyrrolidone as a binder indifferent ratios for 
the two formulae. 
· Saccharin was used from three to five time of active ingredient and 
the best one it was used in ratio five times to active ingredient. 
·  Saccharine itself can be used as a binder.   
· Tablet weight in these two formulae 1600 mg and 2000 mg can be 
used in two tablets to be easy to carry, handle, stand packaging and 
transportation. 
· Micro crystalline cellouse (Avicil) 5% is used as disintegrating 
agent and glidant and lubricant. 
· Mg stearte and Talc powder combinations as lubricant and glidant. 
· Vanillin was used as flavoring agent.   
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3.5.2. Direct Compression:  
    As its name implies, Direct Compression consists of compression 
of tablets directly from powdered material without modifying the 
physical nature of the material itself. Formerly, direct compression 
as the method of tablet manufacture was reserved for small group 
of crystalline chemicals having all the physical characteristics 
required for the formation of a good tablet (2).    
   Ciprofloxacin is mixed with lactose to improve compression 
characteristic then NaHCO3 and saccharine sodium four times 
(active ingredient) were added to active ingredient and mixed well 
and named (A). In another mortar, specified amount of tartaric acid 
and citric acid were weighed accurately and named (B). Then (A) 
and (B) were mixed in third mortar and specified amount of 
banana and vanillin flavor was added and then the whole mixture 
was passed through a sieve for more mixing.  
   One percent of guar is used in dry form for all formula, vanillin 
was added as flavor agent. The powder was put in an oven for 
drying and then tableting machine (2) (13).     
3.6. Quality Control Tests: 
3.6.1. Weight Variation Test:  
   In this test all the tablets of different batches and manufactures 
and the new formula were used to check uniformity in weight, to 
avoid variation in doses. 
20 tablets were taken randomly from each batch and weighed 
individually. Average weight is calculated. 
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  The weights of individual tablets are compared with average 
weight already calculated. 
Then calculate the standard deviation of the tablet from the 
equation: Standard deviation=   
Where: 
     W is the weight of individual tablet  
      is the average weight  
      n is the number of tablet 
;ϭϰͿ 
  The percent deviation is then compared with the monograph for 
compliance according to USP pharmacopeia.      
Table (3-1): USP Requirement for Weight Variation Test 
Tablet Weight Deviation Percent 
More than 300mg 5% 
                                          
3.6.2. Hardness Test: 
    The crushing strength was determined with a tablet hardness 
tester. Tablets were randomly selected from each brand and new 
formula and then the pressure at which each tablet was crushed 
was recorded and the hardness value obtained. (16) 
Mean of hardness was calculated from the:                                                                                                                   
                                     
 
The test was repeated 3 times, and the average was taken (16). 
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Figure (3-) 
Calibration Curve of Pure Ciprofloxacin HCl (?  270) 
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Note: Five brands of ciprofloxacin as shown in table (3-1) were 
purchased from retail pharmacies in Khartoum state. Pure 
ciprofloxacin HCl powder was obtained as a gift from a research 
college. The reagents utilized include hydrochloric acid and ferric 
chloride. (16) 
3.6.3. Assay: 
    A solution of 1% w/v ferric chloride was freshly prepared, as 
well as 100 mcg/ml of pure ciprofloxacin (HCl).  Five tablets from 
each brand were crushed and 100 mg of the powdered samples 
were weighed. Dissolved in 100 ml 0,1N hydrochloric acid (HCl) 
and further dilution was made to obtain 100mcg/ml for each brand. 
To five ml of each brand with the pure sample, 1 ml of ferric 
chloride was added and made up to 50 ml with 0.1N HCl. The 
absorbance of each sample was taken at 438? ( nm) against the 
blank reagent (1ml ferric chloride solution made up to 50 ml with 
0.1NHCl)with an ultraviolet spectrophotometer (Jenway, UK).The 
percentage content was calculated for each brand by using 
calibration curve already prepared according to monograph (14). 
3.6.4. Friability Test: 
  It is used to ensure the ability of the tablets to withstand abrasion 
in packing, handling and transporting. 10 effervescent tablets were 
weighed and placed in tumbling chamber of friability test 
apparatus which is rotated for four minutes at speed of 25 r.p.m the 
tablets are weighed before and after friability procedure using a 
Roche friability tester (Erweka Gmbh, Germany) and then the 
result was calculated from:(14) 
WeightŽĨϭϬƚĂďůĞƚƐďĞĨŽƌĞĨƌŝĂďŝůŝƚǇ - ǁĞŝŐŚƚŽĨϭϬƚĂďůĞƚƐĂŌĞƌĨƌŝĂďŝůŝƚǇ×ϭϬϬ 
                           tĞŝŐŚƚŽĨϭϬƚĂďůĞƚƐďĞĨŽƌĞĨƌŝĂďŝůŝƚǇ 
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 3.6.5. Disintegration Test: (USB 2008 & BP 1998) 
   The tablet disintegration test was carried out to detect the factors 
that would affect the rate of absorption of drugs and hence 
bioavailability. 
  Six tablets were taken from each brand and used for the test in 
stated monograph USP Disintegration Test. 
Each of the six tablets was placed in a plastic tube which was open 
at one end the other and was fitted with a rust proof no 10 mesh 
sieve and was covered in a water bath. 
   The tube was suspended in a water-bath which was 
thermostatically maintained at a temperature of 37, 5 Co. 
  The tubes were moved up and down at constant rate. Then the 
disintegration time was noted when all tablets have disintegrated 
and passed through the sieve. 
             ;ϭϰͿ - (ϭϲͿ 
3.6.6. Dissolution Test: 
    The dissolution test was undertaken using (USP apparatus1) 
(basket method) in six replicates (six tablets for each brand). The 
dissolution medium was 900ml 0.1NHCl which was maintained at 
37 0.5 Co. In all the experiments, 5ml of dissolution sample was 
withdrawn at 45 min and replaced with equal volume to maintain 
sink condition. 
    Samples were filtered and assayed by ultraviolet 
spectrophotometer at 277?  (nm) and compared to standard. 
   The concentration of each sample was determined from a 
calibration curve obtained from pure samples of ciprofloxacin 
according to the monograph. (14)- (16)  
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3.6.7. Microbiological Test: 
  Microbiological test was carried out for new formula in four 
isolated laboratory species to inhibit and ensure the effectiveness 
of the antibiotics. And those species are Salmonella typhi, 
Salmonella para, Staph. Aureus and Escherechia coli (15).  
3.6.7.1. Ciprofloxacin Sensitivity Test using Disc diffusion Kirby-Bauer:  
   Sensitivity Test: 
  For each test and standard 1mg is taken and dissolved in 10 ml 
distilled water then 1ml was taken from it and dissolved in other10 
ml distilled water.(15)  
  Antibiotic disc preparation: 
- Filter paper was cut into small disks of about 4 mm in diameter 
then it enclosed in a sealed container and sterilized in oven. 
- Halve number of the disks impregnated with ciprofloxacin test 
suspension and the others with standard suspension then the disks 
are dried in oven at 60C°  for 20 minutes (serial dilution was made 
to obtain concentration 10µg/ml as follow: 1mg was dissolve in 
10ml and then 1ml was taken and dissolve in another 10 ml).       
      Dilution factor=   (R*V) 
                                       O 
Where:  
R is required concentration, 
V is required volume 
 O is origin concentration    
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 Inoculums was prepared from each bacterium under test 
- Staphylococcus aureus 
- E. coli 
- Salmonella species 
   Inoculums preparation is the most important step in any 
susceptibility test. Inocula are prepared directly by inoculating 
colonies grown overnight on an agar plate, into broth media. Then 
the numbers of bacteria tested was standardized using McFarland 
turbidity standards (15).  
  McFarland turbidity standards: The McFarland 0.5 standard is 
used, which contains 99.5 ml of 1% sulfuric acid and 0.5 ml of 
1.175% barium chloride, this solution is dispensed into tubes 
comparable to those used for inoculums preparation.  
  The McFarland 0.5 standard provides turbidity comparable to that 
of a bacterial suspension containing 1.5î108CFU/ml (15). 
Inoculation and incubation:  
   After preparation of standard inoculums suspension, a sterile 
cotton swab is dipped into the suspension, pressed to remove 
excess liquid, and then swabbed evenly across the surface of a 
Mueller Hinton agar plate (plates of 9mm are used). (Each 
inoculum suspension was inoculated into three media labeled test 
(T), standard (S) and control(C)). 
- Within 15 minutes of inoculation, the individual ciprofloxacin 
disks (one disc per plate) are applied to the agar media with a 
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forceps and gently pressed to ensure contact with the agar. 
(Koletar, 2000) 
- The ciprofloxacin Test disks are applied in the plates labeled (T) 
- The ciprofloxacin Standard disks are applied in the plates 
labeled(S). While other plate’s labeled (c) without antibiotic disks 
were used to control growth. 
- Within 15 minutes of disks placement, plates are inverted and 
placed in a 37 C°  for 18 hours (15). 
- After incubation the plates were examined, to make certain the 
test organisms has grown satisfactory, the diameter of each 
inhibition zone is measured using ruler or calipers.(15) 
 - Once zone measurements have been made, the millimeter 
reading for each brand and effervescent formula are compared with 
that specified in the interpretive tables of the NCCLS documents.   
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. Results 
Table (4-1): Weight Variation of Twenty Tablets for Brand A1 B.N 83683 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 752.2 16.6 275.6 
2 755.5 13.3 176.9 
3 757.5 11.3 127.7 
4 759.0 9.8 96.0 
5 761.3 7.5 56.3 
6 761.6 7.2 51.8 
7 761.7 7.1 50.4 
8 762.5 6.3 39.7 
9 763.7 5.1 26.0 
10 766.7 2.1 4.4 
11 768.3 0.5 0.3 
12 768.6 0.2 0.0 
13 771.5 2.7 7.3 
14 773.5 4.7 22.1 
15 775.1 6.3 39.7 
16 776.6 7.8 60.8 
17 779.8 11.0 121.0 
18 783.7 14.9 222.0 
19 788.4 19.6 384.2 
20 788.5 19.7 388.1 
Mean = ? (weight of 20 tablets) = 153757 = 768.8 mg 
              Number of tablets           20 
Standard deviation= =  = =10.6 mg 
Deviation % = (Standard Deviation /Mean) %=( 10.6/768.8)%=1. 379% 
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Table (4-2): Weight Variation of Twenty Tablets for Brand A2 B.N 83685 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 750.1 17.3 299.3 
2 751.2 16.2 262.4 
3 760.5 6.9 47.6 
4 761.6 5.8 33.6 
5 762.8 4.6 21.6 
6 763.0 4.4 19.4 
7 765.4 2.0 4.0 
8 765.6 1.8 3.2 
9 766.1 1.3 1.7 
10 769.5 2.1 4.4 
11 770.0 2.6 6.8 
12 770.0 2.6 6.8 
13 770.1 2.7 7.3 
14 770.6 3.2 10.2 
15 771.0 3.6 13.0 
16 772.9 5.5 30.3 
17 773.0 5.6 31.4 
18 775.0 7.6 57.8 
19 776.6 9.2 84.6 
20 782.8 15.4 237.2 
 
Mean = ? (weight of 20 tablets) = 15347.8 = 767.4 mg 
               Number of tablets           20 
Standard deviation= =  = =7.9 mg 
Deviation % = (Standard Deviation /Mean) %=( 7.9/767.4)%=1. 029% 
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Table (4-3): Weight Variation of Twenty Tablets for A3 Brand B.N 83690 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 750.1 18.4 338.6 
2 751.2 17.3 299.3 
3 755.4 13.1 171.6 
4 758.9 9.6 92.2 
5 759.0 9.5 90.3 
6 759.1 9.4 88.4 
7 761.2 7.3 53.3 
8 765.1 3.4 11.6 
9 770.1 1.6 2.6 
10 770.1 1.6 2.6 
11 771.0 2.5 6.3 
12 771.1 2.6 6.8 
13 771.1 2.6 6.8 
14 771.2 2.7 7.3 
15 778.2 9.7 94.1 
16 781.0 12.5 156.3 
17 781.1 12.6 158.8 
18 781.2 12.7 161.3 
19 781.9 13.4 179.6 
20 781.9 13.4 179.6 
 
Mean = ? (weight of 20 tablets) = 15369.9 = 768.5 mg 
               Number of tablets           20 
Standard deviation= =  = сϭϬ͘ϱŵŐ 
Deviation % = (Standard Deviation /Mean) %=( 10.5/768.5)%=1. 366% 
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 Table (4-4): Weight Variation of Twenty Tablets for Brand B1 B.N tfx17 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 772.3 29.9 894.0 
2 779.4 22.8 519.8 
3 782.6 19.6 384.2 
4 790.6 11.6 134.6 
5 793.7 8.5 72.3 
6 798.1 4.1 16.8 
7 802.1 0.1 0.0 
8 802.6 0.4 0.2 
9 803.0 0.8 0.6 
10 803.5 1.3 1.7 
11 807.3 5.1 26.0 
12 808.4 6.2 38.4 
13 808.6 6.4 41.0 
14 808.9 6.9 47.6 
15 809.8 7.6 57.8 
16 810.7 8.5 72.3 
17 810.9 8.7 75.7 
18 814.4 12.2 148.8 
19 814.9 12.7 161.3 
20 827.3 25.1 630.0 
 
Mean = ? (weight of 20 tablets) = 16043.1 = 802.2mg 
              Number of tablets           20 
Standard deviation= =  = =13.2 mg 
Deviation % = (Standard Deviation /Mean) %=( 13.2/802.2)%=1. 645% 
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Tab le (4-5): Weight Variation of Twenty Tablets for Brand B2 B.N tfx18 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 789.3 15.4 237.2 
2 791.5 13.2 174.2 
3 791.8 12.9 166.4 
4 792.0 12.7 161.3 
5 798.0 6.7 44.9 
6 798.5 6.2 38.4 
7 799.4 5.3 28.1 
8 800.0 4.7 22.2 
9 800.0 4.7 22.1 
10 801.1 3.6 13.0 
11 802.9 1.8 3.2 
12 806.6 1.9 3.6 
13 807.3 2.6 6.8 
14 807.8 3.1 9.6 
15 808.6 3.9 15.2 
16 808.8 4.1 16.8 
17 809.5 4.8 23.0 
18 819.7 15.0 225.0 
19 819.7 15.0 225.0 
20 840.7 36.0 1296 
 
Mean = ? (weight of 20 tablets) = 16093.2 = 804.7 mg 
              Number of tablets            20 
Standard deviation= =  = =12.0 mg 
Deviation % = (Standard Deviation /Mean) %=( 12.0/804.7)%=1. 491% 
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Table (4-6): Weight Variation of Twenty Tablets for Brand B3 B.N tfx21 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 785.0 25.5 650.3 
2 785.1 25.4 645.2 
3 798.9 11.6 134.6 
4 801.0 9.5 90.3 
5 801.0 9.5 90.3 
6 805.5 5.0 25.0 
7 806.5 4.0 16.0 
8 806.8 3.7 13.7 
9 808.1 2.4 5.8 
10 808.9 1.6 2.6 
11 812.4 1.9 3.6 
12 815.4 4.9 24.0 
13 815.6 5.1 26.0 
14 817.0 6.5 42.3 
15 819.0 8.5 72.3 
16 819.2 8.7 75.7 
17 819.3 8.8 77.4 
18 825.9 15.4 237.2 
19 826.2 15.7 246.5 
20 832.8 22.3 497.3 
 
Mean = ? (weight of 20 tablets) = 16209.6 = 810.5 mg 
               Number of tablets            20 
Standard deviation= =  = = 12.5 mg 
Deviation % = (Standard Deviation /Mean) %=( 12.5/810.5)%=1. 542% 
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Table (4-7): Weight Variation of Twenty Tablets for Brand C1 B.N k0097014 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 880.1 26.6 707.6 
2 885.7 11.0 121.0 
3 896.0 10.7 114.5 
4 899.5 7.2 51.8 
5 901.8 4.9 24.1 
6 902.0 4.7 22.9 
7 902.2 4.5 20.3 
8 904.1 2.6 6.8 
9 904.2 2.5 6.3 
10 906.6 0.1 0.0 
11 908.9 2.2 4.8 
12 908.9 2.2 4.8 
13 909.0 2.3 5.3 
14 913.4 6.7 44.9 
15 914.1 7.4 54.8 
16 914.3 7.6 57.8 
17 916.5 9.8 96.0 
18 917.0 10.3 106.1 
19 921.6 14.9 222.0 
20 928.7 22.0 484.0 
 
Mean = ? (weight of 20 tablets) = 18134.6 = 906.7 mg 
               Number of tablets           20 
Standard deviation= =  = =10.6 mg 
Deviation % = (Standard Deviation /Mean) %=( 10.6/906.7)%=1.169% 
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Table (4-8): Weight Variation of Twenty Tablets for Brand C2 B.N k0097021 
No. 
Weight of 
Tablet(mg) 
|w – w
-
|   (w – w
-
)
Ϯ 
1 906.0 12.0 144.0 
2 906.0 12.0 144.0 
3 906.1 11.9 141.6 
4 906.1 11.9 141.6 
5 911.0 7.0 49.0 
6 912.5 5.5 30.3 
7 913.9 4.1 16.8 
8 915.2 2.8 7.8 
9 916.4 1.6 2.6 
10 917.0 1.0 1.0 
11 917.1 0.9 0.8 
12 918.0 0.0 0.0 
13 918.2 0.2 0.0 
14 919.0 1.0 1.0 
15 920.1 2.1 4.4 
16 922.9 4.9 24.0 
17 923.1 5.1 26.0 
18 924.4 6.4 41.0 
19 942.3 24.3 590.5 
20 944.3 26.3 691.7 
 
Mean = ? (weight of 20 tablets) = 18359.6 = 918.0mg 
               Number of tablets           20 
Standard deviation= =  = =10.4 mg 
Deviation % = (Standard Deviation /Mean) %=( 10.4/918)%=1.133% 
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Table (4-9): Weight Variation of Twenty Tablets for Brand C3 B.N k0097028 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 891.2 18.2 331.2 
2 891.2 18.2 331.2 
3 892.3 17.1 292.4 
4 893.4 16 256 
5 895.2 14.2 201.6 
6 896.6 12.8 163.8 
7 904.1 5.3 28.1 
8 906.0 3.4 11.6 
9 906.6 2.8 7.8 
10 907.6 1,8 3.2 
11 909.1 .3 0.1 
12 913.5 4.1 16.8 
13 915.0 5.6 31.4 
14 916.6 7.2 51.8 
15 918.9 9.5 90.3 
16 920.3 10.9 118.8 
17 922.4 13 169 
18 927.3 17.9 320.4 
19 933.7 24.3 590.5 
20 936.8 27.4 331.2 
 
Mean = ? (weight of 20 tablets) = 18187.8 = 909.4 mg 
              Number of tablets            20 
Standard deviation= =  = = 13.5 mg 
Deviation % = (Standard Deviation /Mean) %=( 13.5/909.4)%=1.484% 
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Table ȋͶ– ͳͲ): Weight Variation for Twenty Tablets for Brand ͳ B.N x020109     
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 746.0 15.6 243.4 
2 749.8 11.8 139.2 
3 758.4 3.2 10.2 
4 758.7 2.9 8.4 
5 759.2 2.4 5.8 
6 759.6 2.0 4.0 
7 760.2 1.4 2.0 
8 760.3 1.3 1.7 
9 761.0 0.6 0.4 
10 762.2 0.6 0.4 
11 762.9 1.3 1.7 
12 763.7 2.1 4.4 
13 764.1 2.5 6.3 
14 764.2 2.6 6.8 
15 764.5 2.9 8.4 
16 764.7 3.1 9.6 
17 766.0 4.4 19.4 
18 766.0 4.4 19.4 
19 769.9 8.3 68.9 
20 769.9 8.3 68.9 
 
Mean = ? (weight of 20 tablets) = 15231.3 = 761.6 mg  
              Number of tablets             20 
Standard deviation= =  ==  = 5.8 mg  
Deviation % = (Standard Deviation /Mean) %=( 5.8/761.6)%=0.762% 
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Table (4 – 11): Weight Variation for Twenty Tablets for Brand D2 B.N x02010 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 751.0 5.6 31.4 
2 751.7 6.9 47.6 
3 752.4 6.2 38.4 
4 752.9 5.7 32.5 
5 753.0 5.6 31.4 
6 753.1 5.5 30.3 
7 755.4 3.2 10.2 
8 758.7 0.1 0.0 
9 759.0 0.4 0.2 
10 759.1 0.5 0.3 
11 760.0 1.4 2.0 
12 761.3 2.7 7.3 
13 761.9 3.3 10.9 
14 762.0 3.4 11.6 
15 762.2 3.6 13.0 
16 762.5 3.9 15.2 
17 763.2 4.6 21.2 
18 764.0 5.4 29.2 
19 764.0 5.4 29.2 
20 764.3 5.7 32.5 
 
Mean = ? (weight of 20 tablets) = 15171.8 = 758.6 mg  
              Number of tablets            20 
Standard deviation= =  =  сϰ͘ϲ mg 
Deviation % = (Standard Deviation /Mean) %=( 4.6/758.6)%=0.606% 
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Table ;ϰ-ϭϮ): Weight Variation for Twenty Tablets for Brand ϯ͘E xϬϮϬϭϴ 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 752.9 7.5 56.3 
2 755.9 4.5 20.3 
3 758.0 2.4 5.8 
4 758.1 2.3 5.3 
5 758.5 1.9 3.6 
6 759.1 1.3 1.7 
7 759.4 1.0 1.0 
8 759.8 0.6 0.4 
9 759.8 0.6 0.4 
10 760.0 0.4 0.2 
11 760.0 0.4 0.2 
12 760.1 0.3 0.1 
13 760.5 0.1 0.0 
14 761.0 0.6 0.4 
15 761.3 0.9 0.8 
16 762.5 2.1 4.4 
17 763.0 2.6 6.8 
18 763.9 3.5 12.3 
19 764.1 3.7 13.7 
20 769.1 8.7 75.7 
 
Mean = ? (weight of 20 tablets) = 5207.6 = 760.4  mg  
               Number of tablets           20 
Standard deviation= =  =  = 3.32 mg 
 Deviation % = (Standard Deviation /Mean) %=( 3.32/760.4)%=0.437%  
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Table (4-13): Weight Variation of Twenty Tablets for Brand E1 B.N 136 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 720.5 12.4 153.8 
2 721.2 11.7 136.9 
3 723.0 9.9 98.0 
4 726.0 6.9 47.6 
5 727.0 5.9 34.8 
6 730.0 2.9 8.4 
7 730.4 2.5 6.3 
8 731.1 1.8 3.2 
9 732.0 0.9 0.8 
10 733.1 0.2 0.0 
11 736.3 3.4 11.6 
12 736.4 3.5 12.3 
13 736.7 3.8 14.4 
14 736.8 3.9 15.2 
15 737.1 4.2 17.6 
16 738.2 5.3 28.1 
17 739.9 7.0 49.0 
18 740.0 7.1 50.4 
19 740.0 7.1 50.4 
20 742.0 9.1 82.8 
 
Mean = ? (weight of 20 tablets) = 14657.3 = 732.9 mg 
               Number of tablets           20 
Standard deviation= =  = ൌ͸Ǥ͸ mg 
Deviation % = (Standard Deviation /Mean) %=( 6.6/732.9)%=0.901% 
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Table (4-14): Weight Variation of Twenty Tablets for Brand E2 B.N 336 
No. 
Weight of 
Tablet(mg) 
|w – w
-
| (w – w
-
)
Ϯ 
1 714.3 14.9 222.0 
2 714.7 14.5 210.3 
3 719.5 9.7 94.1 
4 720.9 8.3 68.9 
5 720.9 8.3 68.9 
6 725.0 4.2 17.6 
7 726.7 2.5 6.3 
8 728.9 0.3 0.1 
9 729.6 0.4 0.2 
10 730.8 1.6 2.6 
11 731.6 2.4 5.8 
12 732.5 3.3 10.9 
13 732.6 3.4 11.6 
14 732.7 3.5 12.3 
15 733.1 3.9 15.2 
16 735.2 6.0 36.0 
17 735.5 6.3 39.7 
18 737.5 8.3 68.9 
19 739.7 10.5 110.3 
20 743.2 14.0 196.0 
 
Mean = ? (weight of 20 tablets) = 14584.9 = 729.2 mg 
               Number of tablets           20 
Standard deviation= =  = =7.9 mg 
Deviation % = (Standard Deviation /Mean) %=( 7.9/729.2)%=1.080% 
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    Table (4-15): Weight Variation of Twenty Tablets for Brand   E3 B.N 256 
No. 
Weight of 
Tablet(mg) |w – w
-
| (w – w
-
)
Ϯ 
1 721.1 11.4 130.0 
2 721.5 11.0 121.0 
3 721.9 10.6 112.4 
4 727.3 5.2 27.0 
5 727.4 5.1 26.0 
6 729.0 3.5 12.3 
7 729.1 3.4 11.6 
8 729.9 2.6 6.8 
9 731.0 1.5 2.3 
10 731.1 1.4 2.0 
11 733.0 0.5 0.3 
12 733.6 1.1 1.2 
13 735.1 2.6 6.8 
14 738.0 5.5 30.3 
15 738.9 6.4 40.9 
16 739.1 6.6 43.6 
17 740.0 7.5 56.3 
18 740.0 7.5 56.3 
19 741.1 8.6 74.0 
20 741.1 8.6 74.0 
 
Mean = ? (weight of 20 tablets) = 14649.2 = 732.5 mg 
              Number of tablets            20 
Standard deviation= =  = =6.6 mg 
Deviation % = (Standard Deviation /Mean) %=( 6.6/732.5)%=0.901% 
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Table (4-16): Summary of Values of Weight Variation for all Brands 
 
Brand Mean (mg) Deviation% 
A1 768.8 1.379 
A2 767.4 1.029 
A3 768.5 1.366 
B1 802.2 1.645 
B2 804.7 1.491 
B3 810.5 1.542 
C1 906.7 1.169 
C2 918.0 1.133 
C3 909.4 1.484 
D1 761.6 0.762 
D2 758.6 0.606 
D3 760.4 0.437 
E1 732.9 0.901 
E2 729.2 1.080 
E3 732.5 0.901 
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 TĂďůĞ;ϰ-ϭϳ): Weight Variation of Effervescent Tablets by Direct Compression Method  
No Weight  of Tablet    
250 mg(AI) 
|w – w
-
| (w – w-)2 
1 944.3 25.7 660.49 
2 912.5 0.6 .0.36 
3 915.2 3.4 11.56 
4 906.0 1.6 2.56 
5 918.2 6.4 40.69 
6 924.4 5.8 33.64 
7 919.0 0.4 0.16 
8 916.4 4.2 17.64 
9 923.1 4.5 20.25 
10 906.1 12.5 156.25 
11 918.0 0.6 0.36 
12 922.9 4.3 18.49 
13 942.3 23.7 561.69 
14 911.0 7.6 57.76 
15 913.9 4.7 22.09 
16 917.1 1.5 2.25 
17 917.0 1.6 2.56 
18 920.1 1.5 2.25 
19 906.1 12.5 156.25 
20 918.2 0.4 0.16 
    
     Mean= ?  (weight of 20 tablets) = 8372   = 918.60 mg 
                     Number of tablets          20 
       Standard deviation= = = ͻǤ͸ 
       Deviation % = (Standard Deviation /Mean) %=( 9.6/918.6)%=1.045% 
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4.1. Hardness Test: (U.S.P) (2008) 
We take the mean of the three different batches of the tablets and 
then compare it with the monograph 
 Table (4-18): Hardness Value for All Brands (39-16) 
  Code Average Hardness value 
(Kg/cm2) 
    A 
    B 
    C 
    D 
    E 
 
10.3 
12.1 
12.87 
11.12 
11.38 
4.2. Disintegration Test: (U.S.B) (2008) & (B.P) (1998) 
Mean Disintegration Time (min) = Total time of tests (minutes)  
                                                                      Number of tests 
Brand A: 
Mean Disintegration Time = 9+10+9  =  9.3 min 
                                                    3 
Brand B: 
Mean Disintegration Time = 21.42+16.33+13  = 16.92 min      
                                                           3                                                                         
 Brand C: 
Mean Disintegration Time=   10.6+6.52+6.58  =   7.9 min 
                                                            3                                                                    
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Brand D:   
Mean Disintegration time = 16.40+16.25+16.30 = 16.31 min 
                                                            3                                                     
Brand E: 
Mean Disintegration time = 1.50+1.34+1.58 = 1.47 min    
         3 
Table (4-19): Samples of Ciprofloxacin Tablets    
Code     Dosage Form Country Origin                                                                          
  A Coated Tablets Switzerland                                                                                                           
  B       Coated Tablets Sudan                                    
  C       Coated Tablets India                                             
  D       Coated Tablets  Sudan                                                
  E       Coated Tablets Sudan 
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FiŐƵƌĞ;ϰ-ϭͿ͗ The Dissolution Profile of Five Brands Ciprofloxacin 
HCl from Sudanese Local Market 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϳϱ 
 
Table (4-20):  Summary of the Quality Control Tests Undertaken 
on the Brands of Ciprofloxacin   
 
 
 
 
 
 
 
 
 
 
 
 
Code 
Assay 
% 
Average 
hardness 
(Kg/cm2) 
Average 
disintegration 
time(min) 
Dissolution 
% 
Deviation 
        % 
Friability  
A 98 10.3 9.3 100 1.379 0.37 
B 97 12.1 16.92 95 1.645 0.20 
C 90 12.87 7.9 94 1.169 0.40 
D 96 11.12 16.31 96 0.762 0.13 
E 95 11.38 1.47 98 0.901 0.24 
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Table (ϰ-Ϯϭ): Effect of Brands of Ciprofloxacin and Standards (pure 
Ciprofloxacin) onBacteria by Inhibition Zone (in mm) 
 
Name of 
Brand 
E.Coli  Inhibition 
 Zone(mm) 
Staph aureus 
Inhibition Zone(mm) 
Salmonella sp 
Inhibition Zone(mm) 
A ϭϲ͘Ϯ ϭϰ͘ϱ ϭϰ 
B ϭϱ ϭϯ͘ϰ ϭϯ͘Ϯ 
C ϭϲ ϭϰ͘ϰ ϭϰ 
D ϭϱ͘ϰ ϭϰ ϭϯ͘ϴ 
E ϭϰ͘ϱ ϭϮ͘ϴ ϭϯ 
Standard (pure 
Ciprofloxacin) 
ϭϴ ϭϲ ϭϱ͘ϴ 
Inhibition zone of different brands in (mm) 
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dĂďůĞ;ϰ-ϮϮ): Effect of All Brands of Ciprofloxacin Compared to Pure 
Sampleof Ciprofloxacin as Standard on Different 
 Species ofMicroorganisms 
 
Name of 
        Brand 
E.Coli  Inhibition 
      Zone % 
Staph. aureus 
Inhibition Zone % 
Salmonella sp 
Inhibition Zone % 
A ϵϬ ϵϬ͘ϲ ϴϴ͘ϲ 
B ϴϯ͘ϯ ϴϯ͘ϴ ϴϯ͘ϱ 
C ϴϴ͘ϵ ϵϬ ϴϴ͘ϲ 
D ϴϱ͘ϲ ϴϴ ϴϳ͘ϯ 
E ϴϬ͘ϱ ϴϬ ϴϮ͘ϯ 
 
/ŶŚŝďŝƟŽŶǌŽŶĞŽĨ^ƚĂŶĚĂƌĚϭϴŵŵŝŶ͘Žůŝ 
/ŶŚŝďŝƟŽŶǌŽŶĞŽĨ^ƚĂŶĚĂƌĚϭϲŵŵŝŶ^ƚĂƉŚĂƵƌĞƵƐ 
/ŶŚŝďŝƟŽŶǌŽŶĞŽĨ^ƚĂŶĚĂƌĚϭϱ͘ϴŵŵin Salmonella sp 
% of Inhibition zone = Inhibition zone of a sample   ×ϭϬϬй    ;ϲͿ 
         Inhibition zone of standard 
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dĂďůĞ;ϰ-Ϯϯ): Effect of Different Brands of Ciprofloxacin by      
 the Surface Area 
Name of 
        Brand 
E.Coli  Inhibition 
Zone(mm)Ϯ 
Staph aureus 
Inhibition 
Zone(mm)Ϯ 
Salmonella sp 
Inhibition Zone   
(mm)Ϯ 
A ϮϬϲ͘ϭ ϭϲϯ ϭϱϰ 
B ϭϳϲ͘ϳ ϭϰϭ ϭϯϲ͘ϴ 
C ϮϬϭ͘Ϭϲ ϭϲϮ͘ϵ ϭϱϰ 
D ϭϴϲ͘ϯ ϭϱϰ ϭϱϰ͘ϯ 
E ϭϲϯ ϭϮϴ͘ϳ ϭϯϮ͘ϳ 
 
Surface area = (? ͬϰͿпϮ 
Where:  
?  ŝƐĂĐŽŶƐƚĂŶƚсϯ͘ϭϰ 
D is diameter of inhibition zone  
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ϰ͘ϯ. Microbiological Results: 
    Reading plates and test interpretation: 
    After incubation the plates were examined and the diameter of 
each inhibition zone was measured using ruler or calipers as in 
above there was found a complete inhibition of the growth in all 
plates in contrast there is standard growth on the control plates. 
The zone of inhibition was found to follow a descending order (A, 
C, D, B and E) in different brands of ciprof loxacin. (15) 
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dĂďůĞ;ϰ-Ϯϰ): Dissolution Time Test of Effervescent Tablet by     
Direct Compression Method (ϯϵ). 
No Dissolution 
Time(seconds) 
| x   –   x
-
 |
 
(x -  x
-
)  
2 
ϭ ϭϬϬ Ϯ͘ϳ ϳ͘Ϯϵ 
Ϯ ϭϬϱ Ϯ͘ϯ ϱ͘Ϯϵ 
ϯ ϵϭ ϭϭ͘ϳ ϭϯϲ͘ϴϵ 
ϰ ϭϬϵ ϲ͘ϯ ϯϵ͘ϲϵ 
ϱ ϭϬϲ ϯ͘ϯ ϭϬ͘ϴϵ 
ϲ ϭϬϱ Ϯ͘ϯ ϱ͘Ϯϵ 
Eсϲ DĞĂŶсϭϬϮ͘ϳ  ? (x – x-)Ϯ=ϮϬϱ͘ϯϰ 
Standard deviation=   
%SD = SD  × 100 
                x¯ 
Where: 
X is the dissolution time 
X
-
is the mean of the dissolution time 
     According to European PŚĂƌŵĂĐŽƉĞŝĂŝƚŵƵƐƚďĞǁŝƚŚŝŶϯϬϬ
seconds and this complies with monograph requirement. So it 
complies within Pharmacopeia monograph. 
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Table (4-25): Weight Variation of Effervescent Tablet 13mm Diameter 
                       (Wet Granulation) 
No Weight of Tablet 
(250 mg(AI)) 
|W– W
-
| (W – W-)2 
1 812.0 4.5 20.3 
2 816.1 8.6 74.0 
3 801.6 5.9 34.8 
4 805.3 2.2 4.8 
5 809.5 2.0 4.0 
6 820.0 12.5 156.3 
7 818.0 10.5 110.3 
8 822.4 14.9 222.0 
9 820.0 12.5 156.3 
10 810.0 2.5 6.3 
11 808.2 0.7 0.5 
12 790.0 17.5 306.3 
13 801.5 6.0 36.0 
14 802.9 4.6 21.2 
15 788.8 18.7 349.7 
16 797.1 10.4 108.2 
17 819.7 12.2 148.8 
18 800.0 7.5 56.3 
19 801.3 6.2 38.4 
20 806.0 1.5 2.3 
 
Mean= ?  (weight of 20 tablets) =16150.7=807.5 mg 
                Number of tablets          20 
Standard deviation= =  = = 9.88 mg 
 Deviation % = (Standard Deviation /Mean) %=( 9.88/807.5)%=1.22% 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϴϮ 
 
  
Table (4-26): Diameter of Effervescent Tablet 13mm Diameter 
No Diameter (mm) |X-X
-
| (X-X
-
)
2 
1 13.30 0.14 0.0196 
2 13.16 0.00 0.0000 
3 13.19 0.03 0.0009 
4 13.25 0.09 0.0081 
5 13.20 0.04 0.0016 
6 13.16 0.00 0.0000 
7 13.16 0.00 0.0000 
8 13.22 0.06 0.0036 
9 13.19 0.03 0.0009 
10 13.19 0.03 0.0009 
11 13.17 0.01 0.0001 
12 13.25 0.09 0.0081 
13 13.16 0.00 0.0000 
14 12.94 0.22 0.0484 
1`5 13.17 0.01 0.0001 
16 13.16 0.00 0.0000 
17 13.06 0.10 0.0100 
18 13.07 0.09 0.0081 
19 13.04 0.12 0.0144 
20 13.16 0.00 0.0000 
 
Mean= ?  (diameter of 20 tablets) =263.2 =13.2 mm 
                    Number of tablet         20 
Standard deviation= =  = =0.081 mm 
Deviation % = (Standard Deviation /Mean) %=( 0.081/13.2)%=0. 614% 
               
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϴϯ 
 
Table (4-27): Thickness of Effervescent Tablet 13mm Diameter 
No Thickness (mm) |X-X
-
| (X-X
-
)
2 
1 4.82 0.06 0.00360 
2 4.89 0.01 0.00010 
3 4.74 0.14 0.01960 
4 4.94 0.06 0.00360 
5 4.85 0.03 0.00090 
6 4.79 0.09 0.00810 
7 4.75 0.13 0.01690 
8 5.05 0.17 0.02890 
9 5.05 0.17 0.02890 
10 5.00 0.12 0.01440 
11 5.00 0.12 0.01440 
12 4.86 0.02 0.00040 
13 4.77 0.11 0.01210 
14 4.84 0.04 0.00160 
15 4.99 0.11 0.01210 
16 4.79 0.09 0.00810 
17 5.04 0.16 0.02560 
18 4.67 0.21 0.04410 
19 4.88 0.00 0.00000 
20 4.89 0.01 0.00010 
 
Mean= ?  (thickness of 20 tablets) =96.808  = 4.88 mm 
                Number of tablets          20 
Standard deviation= =  = =0.1132 mm 
Deviation % = (Standard Deviation /Mean) %=( 0.1132/4.88)%=2.32% 
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dĂďůĞ;ϰ-Ϯϴ): Weight Variation of Effervescent Tablet ϮϬŵŵŝĂŵĞƚĞƌ 
                        (Wet Granulation) 
No Weight of Tablet 
20mm (0.250 gm) 
|W-W
-
| (W-W
-
)
2 
1 1584 15.7 246.5 
2 1586 13.7 187.7 
3 1590 9.7 94.1 
4 1619 19.3 372.5 
5 1609 9.3 86.5 
6 1580 19.7 388.1 
7 1587 12.7 161.3 
8 1600 0.3 0.1 
9 1601 1.3 1.7 
10 1598 1.7 2.9 
11 1610 10.3 106.1 
12 1590 9.7 94.1 
13 1600 0.3 0.1 
14 1608 8.3 68.9 
15 1585 14.7 216.1 
16 1620 20.3 412.1 
17 1587 12.7 161.3 
18 1622 22.3 497.3 
19 1600 0.3 0.1 
20 1618 18.3 334.9 
 
Mean= ?  (weight of 20 tablets) =31994=1599.7 mg 
                   Number of tablets         20 
Standard deviation= = = =13.44 mg 
Deviation % = (Standard Deviation /Mean) %=( 13.44/1599.7)%=0.84% 
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dĂďůĞ;ϰ-Ϯϵ): ŝĂŵĞƚĞƌŽĨīĞƌǀĞƐĐĞŶƚdĂďůĞƚϮϬmm   
No Diameter of Tablet 
20 (mm) 
 |X-X
-
| (X-X
-
)
2 
1 20.03 0.0325 0.00106 
2 20.06 0.0025 0.00001 
3 20.06 0.0025 0.00001 
4 20.09 0.0275 0.00076 
5 20.10 0.0375 0.00141 
6 20.07 0.0075 0.00006 
7 20.05 0.0125 0.00016 
8 20.03 0.0325 0.00106 
9 20.00 0.0625 0.00391 
10 20.09 0.0275 0.00076 
11 20.08 0.0175 0.00031 
12 20.06 0.0025 0.00001 
13 20.05 0.0125 0.00016 
14 20.04 0.0225 0.00051 
15 20.03 0.0325 0.00106 
16 20.07 0.0075 0.00006 
17 20.07 0.0075 0.00006 
18 20.10 0.0375 0.00141 
19 20.09 0.0275 0.00076 
20 20.08 0.0175 0.00031 
 
Mean= ?  (diameter of 20 tablets) = 401.25=20.1 mm 
                Number of tablets            20 
Standard deviation= =  = =0.0272 mm 
Deviation % = (Standard Deviation /Mean) %=( 0.0272/20.1)%=0.1353% 
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dĂďůĞ;ϰ-ϯϬ): dŚŝĐŬŶĞƐƐŽĨīĞƌǀĞƐĐĞŶƚdĂďůĞƚϮϬmm Diameter 
No Thickness of Tablet 
20 (mm) 
|X-X
-
| (X-X
-
)
2 
1 3.96 0.105 0.01103 
2 3.96 0.105 0.01103 
3 4.06 0.005 0.00003 
4 4.09 0.025 0.00063 
5 4.10 0.035 0.00123 
6 4.70 0.635 0.40323 
7 4.10 0.035 0.00123 
8 4.10 0.035 0.00123 
9 4.00 0.065 0.00423 
10 3.98 0.085 0.00723 
11 3.96 0.105 0.01103 
12 3.96 0.105 0.01103 
13 4.09 0.025 0.00063 
14 4.09 0.025 0.00063 
15 3.96 0.105 0.01103 
16 4.01 0.055 0.00303 
17 4.00 0.065 0.00423 
18 4.09 0.025 0.00063 
19 4.06 0.005 0.00003 
20 4.03 0.035 0.00123 
 
Mean= ?  (thickness of 20 tablets) =81.3=4.1 mm 
                   Number of tablets       20 
Standard deviation= =  = =0.1597 mm 
Deviation % = (Standard Deviation /Mean) %=( 0.1597/4.1)%=3.89% 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϴϳ 
 
dĂďůĞ;ϰ-ϯϭ): ,ĂƌĚŶĞƐƐsĂůƵĞƐĨŽƌ&ŽƌŵƵůĂKŶĞϭϯmm Diameter 
Tablets Hardness (kg/cmϮ) 
ϭ ϴ͘ϲϬ 
Ϯ ϴ͘ϰϬ 
ϯ ϳ͘ϱϬ 
ϰ ϴ͘ϳϬ 
ϱ ϳ͘ϯϰ 
ϲ ϳ͘ϭϰ 
ϳ ϴ͘ϯϯ 
ϴ ϳ͘ϳϱ 
ϵ ϳ͘ϳϱ 
ϭϬ ϲ͘ϲϰ 
 
Hardness=?  (ŚĂƌĚŶĞƐƐŽĨϭϬƚĂďůĞƚƐͬϭϬͿ 
                 с;ϳϴ͘ϭϱͬϭϬͿсϳ͘ϴϮ kg/cmϮ 
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dĂďůĞ;ϰ-ϯϮ): ,ĂƌĚŶĞƐƐsĂůƵĞƐĨŽƌ&ŽƌŵƵůĂdǁŽWƵŶĐŚϭϯmm Diameter 
Tablets Hardness (kg/cmϮ) 
ϭ ϰ͘ϴϬ 
Ϯ ϲ͘Ϭϳ 
ϯ ϰ͘ϱϬ 
ϰ ϱ͘Ϭϵ 
ϱ ϰ͘ϴϬ 
ϲ ϯ͘ϱϬ 
ϳ ϱ͘ϱϰ 
ϴ ϱ͘ϯϬ 
ϵ ϱ͘ϲϬ 
ϭϬ ϱ͘ϵϭ 
 
Hardness=?  (ŚĂƌĚŶĞƐƐŽĨϭϬƚĂďůĞƚƐͬϭϬͿ 
                 с;ϱϭ͘ϭϭͬϭϬͿсϱ͘ϭ kg/cmϮ 
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dĂďůĞ;ϰ-ϯϯ): ,ĂƌĚŶĞƐƐsĂůƵĞƐĨŽƌ&ŽƌŵƵůĂdǁŽWƵŶĐŚϮϬmm Diameter 
Tablets Hardness (kg/cmϮ) 
ϭ ϰ͘ϱϬ 
Ϯ ϱ͘ϴϮ 
ϯ ϱ͘ϱϴ 
ϰ ϱ͘ϵϱ 
ϱ ϰ͘ϵϲ 
ϲ ϰ͘ϱϬ 
ϳ ϱ͘ϬϬ 
ϴ ϱ͘ϲϬ 
ϵ ϰ͘ϱϬ 
ϭϬ ϱ͘ϭϬ 
 
Hardness=?  (ŚĂƌĚŶĞƐƐŽĨϭϬƚĂďůĞƚƐͬϭϬͿ 
                 с;ϱϭ͘ϱϭͬϭϬͿсϱ͘Ϯ kg/cmϮ 
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dĂďůĞ;ϰ-ϯϰ): Dissolution of īĞƌǀĞƐĐĞŶƚdĂďůĞƚWƵŶĐŚϭϯmmDiameter 
 
Number of Tablet 
Time of Dissolution of 
īĞƌǀĞƐĐĞŶƚdĂďůĞƚWƵŶĐŚϭϯ 
(Second) 
ϭ ϭϴϬ 
Ϯ ϭϴϱ 
ϯ ϭϳϱ 
ϰ ϭϵϬ 
ϱ ϭϵϴ 
 
Mean of Dissolution Time = ϵϮϴ сϭϴϱ͘ϲ second 
                                                    ϱ 
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dĂďůĞ;ϰ-ϯϱ): Dissolution of īĞƌǀĞƐĐĞŶƚdĂďůĞƚWƵŶĐŚϮϬmmDiameter 
 
Number of Tablet 
Time of Dissolution of 
īĞƌǀĞƐĐĞŶƚdĂďůĞƚWƵŶĐŚϮϬ 
(Second) 
ϭ ϭϳϱ 
Ϯ ϭϳϬ 
ϯ ϭϲϬ 
ϰ ϭϲϱ 
ϱ ϭϳϬ 
 
Mean of Dissolution Time = ϴϰϬ сϭϲϴ second 
                                                    ϱ 
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dĂďůĞ;ϰ-ϯϲ): Friability and PH Values for the Two Effervescent 
Tabletsϭϯmm Diameter and ϮϬŵŵŝĂŵĞƚĞƌ 
Type of Tablet Friability Test PH of solution 
ϮϬŵŵ Tablet  Ϯ͘ϲ% ϲ͘ϭϱ 
ϭϯŵŵ Tablet  ϭ͘ϵ% ϲ͘ϭϳ(for Two Tablet) 
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&ŝŐƵƌĞ;ϰ-ϮͿ͗ Dissolution Profile for Brands and Two Types of 
Formula 
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TablĞ;ϰ-ϯϳ): Summary of the Quality Control Tests Undertaken on the Two 
Types of the Ciprofloxacin Effervescent Tablets  
Effervescent 
Tablet 
Friability Hardness 
(Kg/cmϮ) 
Deviation
% 
pH Assay 
% 
Mean of 
Dissolution 
Time (min) 
 
Direct 
Compression 
ϯ͘ϱ ϰ͘ϱ ϭ͘Ϭϰϱ ϲ͘ϬϮ ϵϴ ϭ͘ϰϯ 
Wet 
Granulation 
ϭϯŵŵƚĂďůĞƚ 
ϭ͘ϵ ϳ͘ϴϮ ϭ͘ϮϮ ϲ͘ϭϱ ϵϳ ϯ͘Ϭϵ 
Wet 
Granulation 
ϮϬŵŵƚĂďůĞƚ 
Ϯ͘ϲ ϱ͘Ϯ Ϭ͘ϴϰ ϲ͘ϭϳ ϵϲ Ϯ͘ϴ 
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dĂďůĞ;ϰ-ϯϴ): Comparison between the Two Types of Effervescent 
Tablet on Different Species of Microorganisms 
Effervescent 
Tablet 
Diameter(mm) Surface Area (mmϮ) 
E. Coli Staph 
aureus 
Salmonella E. Coli Staph aureus Salmonell
a 
Direct 
Compression 
ϭϳ ϭϱ ϭϰ͘ϴ Ϯϲϲ͘ϵ ϭϳϲ͘ϳ ϭϳϮ 
Wet 
Granulation 
ϭϴ ϭϱ͘ϱ ϭϱ͘ϰ Ϯϱϰ͘ϯ ϭϴϴ͘ϲ ϭϴϲ͘Ϯ 
 
In two types of effervescent tablet (wet granulation method and 
direct compression method) the zone of inhibition is slightly larger 
in wet granulation method than in direct compression method this 
might be due to good distribution of active ingredient. 
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. Discussion 
5.1. General Discussion: 
   Effervescent tablets are convenient, easy to use, pre-measured 
dosage forms that are already in solution when ingested (38). 
Effervescent mixtures have been moderately popular over the years 
since along with medicinal value of the particular preparation, they 
offered the public ionic dosage form that was interesting to prepare. 
In addition, they provided a pleasant taste due to carbonation which 
held to mask the taste of objectionable materials (13).Over the earth 
since along with the medicinal value of the particular preparation; 
they offered republic ionic dosage form that was interesting to 
prepare (38). In addition they provide a pleasant taste due to 
carbonation, (CO2 covering testing bables of the tongue) which 
helped to mask the unpleasant taste of objectionable materials to 
become palatable (13).  
  To reduce the cost of medicines especially for the low income 
groups of developing countries, the world health organization 
(WHO) has continuously advocated the use of generic brands. (18),     
But this approach has not provided sufficient evidence for the 
substitution of one brand for another. The difference in cost 
between a brand and generic medicine may be as high as 90%. (19) 
    Generic substitution could be considered when a generic copy of 
a reference drug contains identical amounts of the same active   
Ingredient in the same dose formulation and route of 
administration as well as meet standards for strength, purity 
quality, and identity (20). 
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   However evidences over the years indicate that marketed 
products with the same amount of active ingredient exhibit marked 
differences in their therapeutic responses (21). 
  Ciprofloxacin is an anti bacterial agent of the class 
fluoroquinolones .It was first sold by Bayer pharmaceuticals. In the 
1990s there were just a few brands in Sudan market but recently 
many brands of ciprofloxacin have flooded the market. The prices 
range from Sudan local currency equivalent of $1.25to$12.50.There 
is a growing concern about this situation. How can a patient know 
if buying a cheaper brand would be cost effective or not? The price 
of the cheapest is ten times lower than the most expensive .The 
increase in the number of generics of ciprofloxacin can be 
attributed to increased prescription of ciprofloxacin. It would 
appear that for most infections, empirically and sometimes after 
laboratories investigations, physicians prescribe ciprofloxacin as 
the first drug of choice. This has resulted in higher demand and the 
need to increase supply and this has led to more importation while 
some indigenous pharmaceutical industries began to produce their 
own brands of ciprofloxacin. For the health care providers to use 
these brands they have to ascertain their efficacy.  
5.2. From the Results: 
      A summary of the results of uniformity of weight, Assay        
 Hardness test, Friability and  Disintegration are as shown in table 
(4-20).Uniformity of weight, assay, disintegration and dissolution 
are compendia standards to assess the quality of tablets while 
hardness and friability are referred to as non-compendial standards 
although friability is now included in united states 
pharmacopeia(14). 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϵϴ 
 
5.2.1. Quality Control Tests: 
5.2.1.1. Weight Variation: 
   Uniformity of weight serves as an indicator to good 
manufacturing practices (GMP) as well as amount of the active 
pharmaceutical ingredient (API).(Ciprofloxacin hydrochloride 
contained in the formulation). Weight variation was carried out for 
all brands of ciprofloxacin, where all the tablets passed the test 
with standard deviation and deviation percent as in table (4-16) 
according to USP specification in table (3-1). (14) 
This result agreed with study by Ngwuluka et al, (2008) and Lawal 
et al, (2009) for a comparison study was done in University of Jos, 
Nigeria. Similar result – Ochekpe et al, (2009) reported that same 
justification for weight variation in comparison study.  
5.2.1.2. Assay 
All the brands complied with the USP specification for assay table 
(4-20) the USP specification is that the content of ciprofloxacin 
HCl should not be less than 90% while BP specifies that the 
content should not be less than 95% and not more than 105% 
however the result ascertains the presence of compendia quantity 
of ciprofloxacin HCl in all the brands.    
5.2.1.3. Hardness Test: 
  The hardness or resistance to crush shows the ability of tablets to 
withstand handling without fracturing or chipping. It can also 
influence friability and disintegration, the hardness of tablet, the 
less friable ones and the more time it takes to disintegration .Brand 
A required the least pressure before fracture while brands C, B, E 
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and D could not break at (5 kg/cm2) with Hardness tester. A force 
about 4kg/cm2 is the minimum requirement for satisfactory tablet. 
Hence the tablets of all brands were satisfactory for hardness (29).  
This result agreed with study by Allen et al, (2004). 
5.2.1.4. Friability Test: 
  All the brands gave less than 0.8% w/w loss in weight with the 
friability test determination; this is less than the official specification 
of 1%w/w (BP 1998). This showed that all the brands could 
withstand abrasion without loss of tablet integrity (16). This result 
agreed with study by Adegbolagun et al, (2007) and Gtu et al, 
(2006). 
5.2.1.5. Disintegration Test:  
  Disintegration could be directly related to dissolution and 
subsequent bioavailability of a drug .A drug in a tablet  is released 
rapidly as the tablet disintegrates ,a critical step for immediate 
release dosage forms because the rate of disintegration affects the 
dissolution and subsequently the therapeutic efficacy of the 
medicine .All the brands complied with compendia specifications 
for disintegration test .The BP specification is that un coated 
tablets should disintegrate within 15 min and film coated tablets 
should disintegrate within 30min while USP specifies that un 
coated and film coated tablets should disintegrate within30min(14). 
This Result agreed with study by Awot et al, (2005). Similar result 
Egzlabher et al, (2006) was reported.  
5.2.1.6. Dissolution Test: 
   The USP and BP specifies that the amount of drug released 
(dissolution should not be less than 80% of the labeled amount at 
30min. All brands complied and passed the dissolution test (14). The 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
  
ϭϬϬ 
 
BCS suggests that for class 1 and in some cases class111 drugs 
85% dissolution in 0.1 in HCL in 45 min insures that the 
bioavailability is comply with requirement of monograph (30). This 
result agreed with study by Ochekpe et al, (2008) and Abubakar et 
al, (2006). 
5.2.1.7. Microbiological sensitivity Test:   
  Tables (4-21), (4-22), (4-23), for the five brands of ciprofloxacin 
by using microbiological sensitivity test to evaluate the 
effectiveness by using McFarland turbidity standards after 
preparation of standard in columns suspension and incubation. The 
diameter of each inhibition zone was found after measuring, using 
a ruler and calibers for each brand as shown in the figure.   (4-24-
a) (4-24-b), it is clear that   arrangement of inhibition zone from 
microbiological results of zones of inhibition brand A > brand C > 
brand D > brand B >E. All brands are active against selected 
bacteria (15). This result agreed with study by Mughal et al, (2009) 
and Asghar et al, (2009).  
5.2.2. Formulation of Effervescent Tablet: 
  Effervescent tablet are convenient, easy to use, pre-measured 
dosage forms that are already in solution when ingested (38). 
Effervescent mixtures have been moderately popular over the years 
since along with medicinal value of the particular preparation, they 
offered the public ionic dosage form that was interesting to prepare. 
In addition, they provided a pleasant taste due to carbonation which 
mask the taste of objectionable materials (13). The tablets were 
formulated by two methods wet granulation method and direct 
compression method. 
5.2.2.1. Improving the Palatability of the Tablet Solution: 
  The effervescent tablets of ciprofloxacin hydrochloride, when 
dissolved in water at first there was very bitter taste, to solve this 
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problem saccharin sodium powder was added to the formulation 
together with vanillin flavor (24)(36). This result agreed with study 
by Wade and Weller (1994). In study by Hussain et al, (1991), 
Gennaro et al, (1995) and Janovasky et al, (1997) selection of 
flavors and saccharin to mask specific types have been suggested. 
Similar finding by Swarbri and Boyland (1990) suggested that 
flavors in pharmasceutical technology for masked bitter taste. 
 Effervescent tablet formulation can be used to enhance solubility 
and might increase the palatability and mask taste. This result 
agreed with study by Niazi et al, (1997) and Pather et al, (2002).  
Guar and gums generally lower the diffusion of bitter substances 
from the saliva to the taste buds, beside the binding effect of them. 
Blasé et al, (1993) and shah et al, (1993).  
5.2.2.2. Processing and Additives:  
  Granulation is a common processing step in the production of 
tablet dosage form. This step can be exploited as a mean for taste 
masking of slightly bitter tasting drug by using some gums and 
polymers (guar) (49). As shown by Appelgren et al, (1990) and 
Eskilson et al, (1991). 
Saccharin gives high binding effect with a few amount of water in 
this formula so a few amount of guar was needed and ten times 
dilution was needed for binder, (from 1% to 0.1%). This result 
agreed with study by Rosco et al that dilution of binder by five 
times decrease the strength of granule for the strength of guar 
further dilution was done. So the hardness results (table 4-37) 
varied according to binder concentration.  
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  In  direct compression  method in which 1% guar and 1% pvp 
with lactose  powder were used in direct compression in dry form 
was found have a good compressibility with wet granulation 
method rather than direct compression method due to ability of 
granules to compress(1). This result agreed with Edward and Joseph 
(2000).  
  In wet granulation method mesh number ten was used for first 
granulation, and resizing with mesh number fourteen to enhancing 
uniformity of distribution and mixing. 
The micro crystalline cellulose (MCC 5% w/w) when added before 
granulation used as disintegrant and after granulation as glident. (1) 
  In effervescent formula potassium carbonate might be used 
instead of sodium bicarbonate for hypertensive patients, and for 
patients taking digoxin.  
  Potassium citrate might be used with effervescent ciprofloxacin to 
give unique combination as anti- ineffective and alkalinizing agent 
in urinary tract infection. 
  Tablet weight in this two formulas 1600 mg (1.600 gm) can be 
use in two divided tablets can be easy to handle and stand 
packaging and transportation.   
  In granulation method lubricant and glident were needed beside 
MCC, talc powder 1.5% (w/w) and Mg stearate 0.75% (w/w), 
increasing concentration of Mg stearate can impaire disintegration 
time because it is hydrophobic ( might hinder solubility time and 
water contact) thus we need aluminum foils or glass tight container 
as package.(1) 
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5.2.2.3. Physical Characterization of the Prepared Tablet:  
a) Weight Variation 
 The weight variation of effervescent tablet (both wet granulation 
method and direct compression method) complies with the 
monograph requirements (table 3-1) and this might be giving an 
indication for homogeneity and uniformity of the active ingredient 
distribution (table 4-37) (39). These results might be due to the 
uniform granulation, good flow, and uniform die filling. 
b) Assay  
The effervescent tablets complied with the USP specification for 
assay table (4-37) the USP specification is that the content of 
ciprofloxacin HCl should not be less than 90% and not more than 
110% while BP specifies that the content should not be less than 
95% and not more than 105% however the result ascertains the 
presence of compendia quantity of ciprofloxacin HCl in 
effervescent tablet.  
c) Hardness 
For the hardness test stating in official monographs (BP1998) with 
normal range of (4- 8)kg, wet granulation showed higher value 
than direct compression which was within the normal range 
mentioned, (table 4-37) but relatively high and this may be due to 
the granules edge have ability to compress and application of high 
pressure of the used tabletting machine. For the same test for 
tablets of 13mm diameter, showed higher value than 20mm 
diameter that might be to size of the tablet and thickness of it. This 
result agreed with study by Sagar et al, (2006) that indicate 
granules in wet granulation method have higher ability to compress 
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rather than direct compression method in formulation of 
effervescent tablets.   
d) Friability  
For shipping and transportation purposes that face the tablets as 
drug product cycle until reaching the user (patients), the friability 
test was performed tablets of both methods percentage loss in wet 
granulation 1.9% it is lower than direct compression method 3.5% 
which can be taken as compliance for wet granulation method 
according to European pharmacopeia 2000 which permitted a loss 
up to 2.5%. High value of direct compression friability test might 
be the powder components have not well compressibility 
properties, and this was solved later by granulation process and 
this result agreed with study by Rudnic et al, (2000) which 
reported that granulation process can be solution for the problems 
in powder that don’t be compressed by direct compression 
method.(1) 
e) Thickness and Diameter 
Both types of formula pass the thickness and diameter test and 
comply for the monograph (tables (4-26), (4-27),(4-29),(4-30)) . 
f) Dissolution  
 The dissolution time of effervescent tablet (direct compression)     
(103sec) and the dissolution time of effervescent tablet (wet 
granulation) 185 second the two types of effervescent tablets 
complied with the pharmacopeia specifications for the effervescent 
tablets, which is up  to 300  seconds (5min)  (European 
pharmacopeia,  2002) table (4-24)(39). The dissolution of tablet 
from direct compression is faster than wet granulation method; this 
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might be high value of hardness of tablets by wet granulation 
method compared to direct compression method. (39) 
  The increase of amount of dissolved drug in effervescent tablets 
at (45 min) comparing to five brands may be due to using of guar 
as binding agent which caught some effervescent granules and 
release them later at that time.  
g) Microbiological Sensitivity Test  
 Antimicrobial susceptibility tests measure the ability of an 
antibiotic or other anti microbial agents under suitable conditions 
to inhibit bacterial growth in vitro for evaluating the safety and 
effectiveness of antibiotic products, several types of antimicrobial 
susceptibility (sensitivity) tests are done.(15)  
 On comparing tablets formulated as effervescent ones (wet 
granulation) inhibition zones were found higher than the direct 
compression ones. This might be due to more distribution of the 
active ingredient by mixing (13). 
5.3. Summary and Conclusion: 
· Post –market monitoring is very crucial for effective clinical 
medicine and this study has emphasized that chemical equivalence 
does not indicate the same effectiveness. Also one drug substituted 
on assumption of chemical equivalence to another brand may not 
give the desired onset of treatment and subsequent therapeutic 
effectiveness. Interestingly from this study, it was understood that 
price may not necessarily indicate effectiveness. Brand E is sold in 
Sudan at an equivalent of $3 but it might be of the same 
effectiveness as brand A (from inhibition zone) which is sold at 
$12.50. Post-market monitoring is very important and crucial for 
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the confirmation of the physicochemical prosperities complying 
with the monographs requirements, to ensure their effectiveness, 
stability and patient’s compliance.  
·  The study also managed to improve the palatability of the drug 
solution, via the utilization of saccharin sodium and vanillin flavor 
and using effervescent formula. 
    Formulation into effervescent tablet is suitable for larger dose 
size which has difficulty in production of a convention tablet due 
to the difficulty in swallowing, besides enhancing solubility and 
masking the taste. 
· Formulating tablet by wet granulation method (when it is 
possible and applicable) is better than in direct compression 
method because of good distribution of active ingredient.  
· Due to the high solubility of the effervescent drug, ciprofloxacin 
was formulated as effervescent tablets to become more effective, 
convenient, and easy to use and swallow. Premeasured dosage 
forms that are already in solution when ingested effervescent 
mixtures have been moderately popular.  
· The effervescent tablets may be very effective in medicine this 
clear from the microbiological sensitivity test which has been 
carried out against different bacteria.  
   The inhibition zones diameters for pure ciprofloxacin when used 
emphases the effectiveness of drug (active ingredient). This reflect 
that there is no incompatibility of various additives between 
different formulae component.(13) 
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5.4. Recommendations: 
1-The monitoring and quality control testing of medicines in 
pharmacies randomly to ensure the good storage conditions might 
ensure drug’s effectiveness.  
2- The effervescent formula is needed and sometimes it is a must 
to enhance palatability of certain drugs. 
 3- The correlation can be made between dissolution rate of    
effervescent tablets as an indication for its effectiveness without in 
vivo studies and that by microbiological inhibition zone sensitivity 
test.  
4- Wet granulation method (when it is applicable) is better than the 
direct compression method; this might lead to good distribution of 
active ingredient.  
5- Effervescent tablet from ciprofloxacin might reduce the 
microbial resistance, and increase patient compliance, and the 
effervescent tablets need well tight container.  
6- The microbiological sensitivity test can be used as an indicative 
for variations of drugs activities in different formulae. 
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